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Abstract 
Drug abuse, including the illicit use of opioids and cocaine, is a critical global 
problem with high social and economic costs.  Given the current lack of selective and 
efficacious pharmacotherapies to treat addiction, it is vital that we gain a better 
understanding of the cellular and molecular targets of drugs of abuse, and how 
modulation of these targets leads to the development of addiction.  Although different 
abused drugs work through different mechanisms of action, addiction is thought to have a 
common pathway, the mesocorticolimbic DA system, which consists of the ventral 
tegmental area (VTA) and reciprocal connections with downstream targets including the 
prefrontal cortex (PFC) and nucleus accumbens (NAc).  Various drugs of abuse, such as 
opioids and cocaine, induce adaptations to excitatory and inhibitory signaling within the 
mesocorticolimbic DA system.  Although drug-induced adaptations to excitatory 
signaling within the mesocorticolimbic DA system have been well characterized, the 
adaptations and importance of inhibitory signaling requires further investigation. G 
protein-coupled receptors (GPCRs) and downstream effectors/second messengers 
represent a major target for drug-induced changes in mesocorticolimbic signaling. G 
protein-gated inwardly rectifying K+ (GIRK) channels are a key downstream target of 
inhibitory GPCRs, including the mu opioid receptor (MOR), gamma-aminobutryic acid 
receptor (GABABR), and the dopamine type 2 receptor (D2R).  GIRK channels have been 
shown to mediate the inhibitory effects of many neurotransmitters in the central nervous 
system, and dysregulation of GPCR-GIRK signaling has been identified in a number of 
disorders, including addiction.  This dissertation focuses on the role of GIRK-dependent 
inhibitory signaling throughout the mesocorticolimbic DA system, and how this form of 
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signaling contributes to the cellular and reward-related behavioral effect of drugs of 
abuse.   
The importance of GIRK-dependent signaling to drug addiction is supported by 
the fact that several drugs of abuse can produce adaptations to the GPCR-GIRK signaling 
cascade.  GIRK-dependent signaling was also believed to be a key regulatory of opioid 
effects within the mesocorticolimbic DA system, thought to ultimately contribute to 
opioid reward.  Here, we challenged the opioid signaling “dogma” and show that GIRK-
dependent signaling in midbrain GABA neurons is not required for disinhibition of VTA 
DA neurons and subsequent opioid-induced motor-stimulation.  Interestingly, it appears 
the unique GIRK2/GIRK3 channel found in VTA DA neurons can modulate the 
behavioral sensitivity to opioids.  In addition, we found that this GIRK2/GIRK3 channel 
can also modulate D2R autoinhibitory feedback signaling of VTA DA neurons and 
cocaine locomotor sensitivity, suggesting it could be a shared mechanism of other drugs 
of abuse as well.  Taken together, these findings demonstrate that GPCR-GIRK inhibitory 
signaling in VTA DA neurons is critical to the molecular and behavioral effects of drugs 
of abuse.  These findings in VTA DA neurons also suggest that the discovery of novel 
compounds that modulate GIRK channel function in a subunit-dependent manner could 
help us prevent and/or treat addiction.   
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I. DRUG ADDICTION 
Drug Abuse refers to inappropriate use of both illicit and legal drugs.  This can 
include repeated use of drugs to produce pleasure, alleviate stress, to avoid reality, and 
using prescription drugs in ways other than prescribed or using someone else’s 
prescription.  Drug addiction corresponds to the DSM definition of substance use 
disorder, which is diagnosed when an individual presents with 2-3/11 symptomatic 
criteria that span four major groupings: impaired control, social impairment, risky use, 
and pharmacological criteria [1].  Illicit use of drugs, such as cannabis, cocaine, heroin, 
and prescription psychotherapeutics, is a critical problem in the United States and 
worldwide.  In 2012, an estimated 23.9 million Americans, 9.2% of the population, 12 
years of age or older were current illicit drug users [2].  Worldwide, an estimated 155-
250 million people 15-64 years of age used illicit substances in 2008, with opioid and 
cocaine abuse among the most common [3, 4]. 
Significant individual and public health concerns arise from the abuse of illicit 
and legal substances.  Drug abuse can cause or contribute to more than 70 medical 
conditions, such as heart disease, pregnancy complications, infectious diseases, or 
accidents and trauma, which require hospitalization and/or long term medical care [5].  
The high prevalence of infectious diseases, like HIV and hepatitis, with IV drug use has 
become an increasing public health concern and complicates individual long term care 
options [6].  Drug abuse also has a high co-occurrence with many psychological 
disorders, which can complicate treatment options.  The financial burden is also high, 
with approximately 2% of GDP in the United States (more than $700 billion a year) spent 
3	  
	  
on health care costs, crime, and lost productivity due to drug use [6, 7].  On average, 16% 
of any state’s budget is devoted  to the costs of addiction and risky drug use, but for every 
dollar spent on addiction and substance abuse, only 2 cents of that goes to prevention and 
treatment [5, 8].  One out of every five Medicaid dollars is spent on hospital care 
attributable to substance abuse [8].  Given the social and economic consequences 
associated with illicit drug use, it is imperative that we gain a better understanding of the 
biological mechanisms that ultimately lead to addiction.  
Drug addiction is a chronic, relapsing brain disorder that is defined as compulsive 
drug seeking and use despite negative consequences to both the user and loved ones [1] 
[9, 10].  Drugs with high abuse liability, such as opioids and cocaine, produce an initial 
state of well-being or euphoria, “rewarding effects”, by acting on the reward center of the 
brain [11-16].   Use of the drug continues in an attempt to recreate the euphoric 
experience and/or avoid undesirable feelings of withdrawal, in turn resulting in a pattern 
of repeated drug use. This repeated drug exposure leads to a variety of neurochemical 
adaptations in the brain that can result in physical dependence, and ultimately, the 
development of addiction.  Current treatment approaches include medication and 
behavioral therapy, and have been shown to be most effective when combined. Treatment 
plans usually begin with monitored detoxification, treatment, and continual care to 
prevent relapse; however it is important to note that no single treatment plan is 
appropriate for everyone.  Behavioral therapy can include individual and group based 
therapy to address mental health and personal issues that may be contributing to the 
substance abuse [17].  To date there are few pharmacologic options that can be used for 
addiction therapy/treatment.  Currently available pharmacotherapies are mainly used to 
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help ease withdrawal or to help prevent relapse and diminish cravings; however, their 
effectiveness is not ideal with a relapse rate of 40-60% [10, 18, 19].  Opioid addicts have 
the highest relapse rate with nearly 80-90% using within the first year following 
abstinence [20].  Inpatient treatment for cocaine addiction has a much higher success rate, 
with around 20-30% relapse rate in the first year following abstinence [21]. With relapse 
rates remaining between 40-60%, vast improvements are needed in our understanding of 
the mechanisms through which drugs with high abuse liability produce their rewarding 
effects in an effort to improve prevention and/or treatment of drug addiction. 
 
II. DRUGS OF ABUSE  
i. Opioids 
The term ‘opiate’, refers to any preparation made from the natural alkaloids of opium 
poppy resin, Papaver somniferum [22, 23]. In contrast, ‘opioid’ refers to compounds 
produced naturally by the opium poppy, as well as compounds that mimic the 
pharmacological effect of opiates. This includes all natural products derived from the 
opium poppy, semi-synthetic and synthetic products, and endogenous opioid peptides 
[24, 25].  Opioids have been used for centuries to treat pain [26-28], but seem to have an 
equally long history of abuse. Records indicate that opium was used by Greeks and 
Romans as far back as the third century B.C. for its analgesic as well as euphoric 
properties [22, 23, 29]. This historical use of opium dating back centuries for pain 
management and anesthesia demonstrates just how effective an analgesic it is, and how 
even with the discovery of other pharmacotherapies to manage pain, opioids remain the 
gold standard of pain relief.  Today the prevalence of opioid use for non-medical 
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purposes, including heroin and prescription opioids, is estimated at >1% of the world’s 
population 15-64 years of age [6]. Moreover, in 2010, the Substance Abuse and Mental 
Health Services Administration reported that approximately 2 million Americans were 
using prescription painkillers non-medically [2], and the number of unintentional 
overdose deaths has more than tripled from 140,000 to 540,000 between 1999 and 2011 
[30]. 
 Morphine is the most widely used opioid to treat both acute and chronic pain [24, 
31-33]. It was first isolated from the opium poppy in 1805 by pharmacist Friedrich 
Wilhelm Adam Sertürner and marketed commercially by Merck Pharmaceuticals in 1827 
[34]. Since its isolation, drug companies have created numerous semi-synthetic 
(hydrocodone, oxycodone, heroin, buprenorphine, etc.) and synthetic (tramadol, fentanyl, 
methadone, etc.) opioid compounds for pain relief, anesthesia, and the treatment of drug 
dependence [24, 25].  Although opioids remain the most effective drugs for the relief of 
pain, many side effects accompany the use of opioid-based drugs. For example, acute use 
can cause constipation, itching, nausea and vomiting, drowsiness/sedation, and 
respiratory depression [24, 35-40].  Chronic use of opioids can result in hyperalgesia, 
hormonal effects, immunosuppression, the development of tolerance and abuse, and 
ultimately addiction [40-48].  To date, our understanding of and ability to disentangle the 
beneficial outcomes associated with opioids (analgesia) from the undesirable side effects 
(tolerance and addiction) is highly limited. 
Opioid dependence and addiction are managed currently with a combination of 
psychosocial therapy and opioid substitution pharmacotherapies, such as methadone and 
buprenorphine, or opioid antagonists, such as naltrexone and naloxone [3, 17, 49].   
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These medications can be used individually or in combination to detoxify the addict, 
gradually taper the amount of opioid used, and to help suppress withdrawal symptoms 
[50].  Optimal results are achieved through office-based opioid treatment and 
psychosocial treatment.  Although effective pharmacotherapies, these medications come 
with their own set of challenges and limitations [51]. Methadone can have a side effect 
profile similar to opioid abuse, including adverse drug interactions and abuse liability [3, 
49]. An additional challenge is that methadone therapy requires daily or regular clinic 
visits leading to lack of compliance and relapse rates of 80-90% [3, 10, 20, 52].  As 
opioid abuse continues to rise, costing society approximately $72 billion per year [53, 
54], it seems imperative that we gain a better understanding of the mechanisms that 
mediate the analgesic versus the addictive effects of opioids, to in turn better prevent or 
better treat these conditions.  
ii. Psychostimulants: Cocaine 
Cocaine has been used for centuries for its euphoric and energizing properties.  
Records indicate that the tribes of Peru, Bolivia, and Columbia have chewed and brewed 
coca leaves for centuries to fight fatigue and hunger as far back as 3000 B.C. [55-57]. 
Cocaine consumption did not become a problem until around 1884, when it was coined a 
“miracle drug” and used in an attempt to treat various disorders [57, 58].  Even with the 
discovery in the 1900s that cocaine holds little therapeutic efficacy, cocaine use has 
continued to remain a global critical problem. The United Nations World Drug Report 
stated that 14.3 million people worldwide reported using cocaine between 2005 and 2006, 
and 1.6 million people in the United States, 0.6% of the population, used cocaine in 2012 
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[2, 4].  Further, cocaine use and abuse continues to be a costly economic and public 
health burden [5-8].   
Cocaine is a ‘psychostimulant’, which refers to a class of drugs that produce a 
transient increase in psychomotor activity with antidepressant or mood-elevating 
properties [59].  Psychostimulants include cocaine, amphetamine, amphetamine 
derivatives, caffeine, and nicotine [60]. The active ingredient in coca leaves, cocaine, was 
isolated by Albert Niemann in 1859 [58].  Following its isolation, cocaine was used in 
numerous tonics and wines that were heavily endorsed by medical professionals from 
1860 to early 1900s [57, 58].  Cocaine was also present in the initial formula of Coca-
Cola.  In the late 1800s, cocaine was used in Western medicine as a local anesthetic and 
minor pain reliever [57, 58].  Once it became clear in the early 1900s that cocaine offered 
little efficacy in treating various disorders and possessed high addictive properties, it was 
removed from all products and labeled as an illicit substance [57, 58, 61].  However, the 
damage was already done and cocaine was here to stay.  Intranasal use of cocaine powder 
became popular again in the 1970s for social-recreational use.  The development of free 
base cocaine, or ‘crack’, in 1974 which could be smoked for a more rapid “high”, 
resulted in an explosion of cocaine abuse and addiction [55, 57, 58].  The ‘crack’ 
epidemic among other illicit substance use caused the United States to wage a “War on 
Drugs” in the 1990s.  Despite these efforts, cocaine use remains an issue today [2].   
 Cocaine and amphetamine have very limited therapeutic use, but are commonly 
abused due to their euphoric, energizing, decreased appetite, and increased alertness 
effects [62].  Other less desirable effects include increased muscle tension, tachypnea, 
hyperpyrexia, tremors, diaphoresis, myocardial infarction and stroke [62-64].  Repeated 
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cocaine use can result in restlessness, irritability, stereotypic behaviors, insomnia, and 
overdose [64-66].  Cocaine overdose can result in serious life-threatening medical 
conditions such as convulsions/seizures, cerebral hemorrhage, and cardiac or respiratory 
failure [67, 68].  
Cocaine dependence and addiction, unlike opioid addiction, is often treated with 
behavioral interventions such as cognitive-behavioral therapy.  There are currently no 
pharmacotherapies that have met the criteria for regulatory approval or acceptance in the 
medical community for the treatment of psychostimulant addiction [62].  However, 
currently there are a number of pharmacologic treatments for psychostimulant-use 
disorders, as defined by the DMSV, in clinical trials [62].  These pharmacotherapies 
include three main categories: naltrexone, disulfiram/anatabuse, and agonist-like 
replacement therapies [69-73].  Although some of these clinical trials seem promising, we 
still have a long way to go toward effective and safe pharmacotherapies for the treatment 
of psychostimulant addiction.  It is important to note that, as we see with other substance 
abuse disorders, treatment of psychostimulant addiction is often most effective when 
combined with the treatment of comorbid psychosocial disorders and/or withdrawal 
symptoms.  Due to the lack of pharmacotherapies available to treat psychostimulant 
addiction, it seems imperative that we gain a better understanding of the mechanisms that 
mediate the “rewarding” effects of cocaine, to in turn better prevent or better treat 
addiction. 
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III. NEUROCIRCUITRY OF REWARD: MESOCORTICOLIMBIC DA 
SYSTEM 
Although various abused drugs work through different mechanisms of action, 
addiction is thought to have a common anatomic substrate, the mesocorticolimbic DA 
system [74, 75].  The mesocorticolimbic DA system is comprised of dopamine (DA) 
neurons originating from the ventral tegmental area (VTA) with axons projecting to 
limbic (nucleus accumbens (NAc)) and cortical (prefrontal cortex (PFC)) nuclei depicted 
in Figure 1.1.  These DA neurons respond to natural rewards important for survival and 
reproduction, such as food, water, and sex, by becoming more active and releasing more 
DA at the synapses of downstream targets [76, 77].  Dysfunction of the 
mesocorticolimbic DA system is associated with addiction and mental health disorders, 
including major depression and schizophrenia [78, 79].  Drugs of abuse, including 
opioids and cocaine, are thought to exert their euphoric effects by hijacking the signaling 
in the brain’s natural “reward circuit”, leading to alterations in DA and other 
neurochemical signaling pathways within this circuit.  These drug-induced alterations in 
“reward circuit” cellular activity can result in various physiological and behavioral 
changes centered on escalating and unregulated intake of the drug, which characterizes 
addiction [79]. 
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Figure 1.1. The mesocorticolimbic DA system.  Cartoon depiction of key players in the 
mesocorticolimbic DA system as discussed here.  VTA DA neurons project to 
downstream targets such as glutamatergic pyramidal neurons of the PFC and GABAergic 
medium spiny neurons (MSN) of the NAc.  The PFC and NAc send reciprocal 
glutamatergic and GABAergic projections back to the VTA.  Abbreviations: Ventral 
tegmental Area (VTA), prefrontal cortex (PFC), nucleus accumbens (NAc), hippocampus 
(HPC).  
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i. Ventral Tegmental Area (VTA) 
The activity of the VTA has been shown to play a key role in the rewarding 
properties of drugs of abuse, with various alterations in VTA signaling depending of the 
class of drug [80]. The VTA, often thought of as the origin of the “reward circuit”, is a 
small nucleus located along the ventral midline of the brain, above the brainstem.  It is 
also referred to as the A10 region, referring to the A10 dopaminergic neuron population, 
which projects to the NAc [81].  However, the VTA is a heterogeneous population of 
neurons consisting of (65%) DA, (30%) gamma-aminobutyric acid (GABA), and (5%) 
glutamate neurons [82-87].   
The relevance of the VTA to drug-induced, reward-related behavior is highlighted 
by several experiments incorporating intracranial lesioning or pharmacological 
manipulations. For example, infusion of opioids into the VTA can evoke reward-related 
behaviors, such as motor-stimulation and conditioned place preference [88-90].  Rodents 
will also work to self-administer opioids directly into the VTA, while cocaine self-
administration can be disrupted by intra-VTA infusion of DA type 1 receptor (D1R) 
antagonists or GABABR agonist (baclofen) [14, 91-94]. In addition, lesions that disrupt 
signaling between the VTA and NAc disrupted cocaine and heroin self-administration 
and heroin-induced locomotor activity [95, 96].  Thus, the VTA is a critical component of 
the intrinsic reward pathway and a neuronal substrate for drug-induced, reward-related 
behaviors.  
ii. Prefrontal Cortex (PFC) 
  The PFC is the most rostral portion of the frontal lobe, which is located in the 
anterior portion of the brain.  It is often thought of as an input association cortex, 
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responsible for decision-making, goal-directed behavior, and processing reward-related 
information [97, 98].  The PFC is critical for executive functions, attention, memory, 
intelligence, and language [97].   Damage to the PFC can produce drastic alterations in 
personality, memory, and emotional state [99-102].  One subregion of importance is the 
medial prefrontal cortex (mPFC), a highly organized structure comprised of 
glutamatergic pyramidal neurons and GABAergic interneurons [97, 103, 104].  The 
mPFC plays a key role in modulating the mesocorticolimbic DA system.  In particular, 
mPFC provides excitatory input that helps regulate the activity of VTA and NAc neurons.  
Within the VTA, mPFC glutamatergic neurons synapse on both of the predominant cell 
types, VTA GABA and DA neurons.  In turn, DA neurons of the VTA project back to the 
mPFC, while VTA GABA neurons project to the NAc, creating a feedback loop to 
regulate mesocorticolimbic cellular excitability [105-107].  
mPFC activation is vital to cognitive functions, including the integration and 
processing of reward-related information [108, 109].  Imaging studies in human cocaine 
addicts show that mPFC function is altered, represented as decreased cerebral blood flow 
and glucose metabolism, during cocaine withdrawal and exposure to cocaine-paired cues 
[110-113].  Rodent studies, involving lesioning or pharmacologic manipulation of the 
PFC, support the contention that the mPFC mediates several aspects of reward-related 
behaviors, including locomotor sensitization, drug-taking behavior, and cue- or drug-
induced relapse [114-119].  For example, infusions of DA receptor antagonists into the 
mPFC decreased drug-primed reinstatement [120, 121].   The glutamatergic output of the 
mPFC to the VTA stimulates DA release to the NAc, triggering a number of drug-
induced adaptations to the VTA and NAc that ultimately underlie the drug-induced 
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alterations in reward-related behavior [122-125]. Thus, the PFC is a critical component of 
the intrinsic reward pathway and a neuronal substrate for drug-induced, reward-related 
behaviors.  
iii. Drug-Induced Adaptations 
Exposure to various drugs of abuse, such as opioids and cocaine, triggers drug-
induced adaptations to excitatory and inhibitory signaling within the mesocorticolimbic 
DA system [75, 80, 126, 127].  Drug exposure triggers an increase in excitatory 
signaling, via increased strength of excitatory synapses in VTA DA neurons [128-130].  
Drug-induced adaptations to excitatory signaling within the mesocorticolimbic DA 
system have been well characterized [75, 80, 90, 126, 127, 131-133].  However, the 
adaptations and importance of inhibitory signaling requires further investigation, 
including the mechanisms of drug-induced changes to inhibitory signaling in the VTA 
and mPFC, and the role they play in the cellular and behavioral effects of drugs of abuse. 
 
IV. INHIBITORY SIGNALING: GPCR-GIRK 
i. G Protein-Coupled Receptors   
A. Structure  
G protein-coupled receptors (GPCRs) form a superfamily of proteins that play a 
vital role in regulating physiology, such as cell growth and development, cardiac 
function, immune function, neurological function, and metabolism [134].  This receptor 
superfamily represents a prominent therapeutic target, with nearly 45-50% of the drugs 
on the market targeting a GPCR [135, 136].  While the GPCR superfamily is highly 
diverse, all members exhibit seven α-helical transmembrane (TM) regions with an 
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extracellular amino-terminus and intracellular carboxy-terminus [137, 138]. GPCRs are 
activated by extracellular binding of various ligands including hormones, proteins, lipids, 
and neurotransmitters [138-142].  Key inhibitory GPCRs relevant to the work discussed 
here include the mu opioid receptor (MOR), gamma-aminobutryic acid receptor 
(GABABR), and the dopamine type 2 receptor (D2R).      
B. Function 
The G protein signaling cascade, comprised of a GPCR, G protein, and 
downstream effectors/second messengers, is a major target for drug-induced changes in 
mesocorticolimbic signaling.  G proteins are comprised of three subunits, Gα, Gβ and Gγ 
that are bound together with the GPCR in the inactive state.  The G protein signaling 
cascade is activated by ligand binding to the GPCR.  Ligand binding triggers a 
conformational change in the GPCR, allowing it to serve as a guanine nucleotide 
exchange factor for the associated G protein [143]. Specifically, the activated GPCR 
catalyzes the exchange of guanosine diphosphate (GDP) bound to the Gα protein for 
guanosine triphosphate (GTP).  The GTP-bound Gα subunit then dissociates from the 
Gβγ subunit, allowing each subunit to bind to various downstream effectors.  The 
intrinsic GTPase activity of the Gα subunit hydrolyzes the bound GTP into GDP, 
promoting the re-association of the Gα and Gβγ subunits and inactivation of the G protein 
signaling cascade [143, 144].  Following the re-association of the GPCR and G protein, 
the GPCR can be activated again in the presence of an agonist.   
The effect of G proteins on neuronal activity depends on subunit identities and 
downstream intracellular targets [145]. Specifically, Gαs and Gαq promote excitatory 
effects within the neuron through the activation of downstream enzymes, adenylyl 
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cyclase (AC) and phospholipase C (PLC), and their subsequent production of second 
messengers.  In contrast, Gαi/o promotes inhibitory changes via inhibition of adenylyl 
cyclase [146-148].   The Gβγ subunit can also modulate neuronal activity through direct 
inhibition of voltage-gated Ca2+ channels and activation of G protein-gated inwardly 
rectifying potassium (K+) (GIRK/Kir3) channels [149-156].    
ii. G protein-gated inwardly rectifying potassium (GIRK) channels  
A. Function and Pharmacology 
Proper functioning of the nervous system requires a balance of excitatory and 
inhibitory signaling, and GIRK channels serve as an important regulator of inhibitory 
control.  GIRK channels are expressed throughout the central nervous system (CNS) and 
act as downstream targets for various Gαi/o-linked GPCRs, such as MOR, GABABR and 
D2R [157-163]. GIRK channels are activated by the direct binding of Gβγ following 
GPCR activation [149].  Activation of GIRK channels produces a postsynaptic efflux of 
potassium from the cell, responsible for hyperpolarization/inhibition of the neuron [164-
166].   
B. Subunits 
Throughout the CNS, GIRK channels serve as an important regulator of cellular 
activity.  Four mammalian GIRK channel subunits have been identified, GIRK1 
(Kir3.1/Kcnj3), GIRK2 (Kir3.2/Kcnj6), GIRK3 (Kir3.3/Kcnj9) and GIRK4 
(Kir3.4/Kcnj5), and have distinct but overlapping expression patterns [164, 165, 167].  
GIRK1, GIRK2, and GIRK3 are widely expressed throughout the nervous system and 
interact to form homotetrameric (homomeric) and heterotetrameric (heteromeric) GIRK 
channels [157, 167].  GIRK4 is primarily found in the heart and a few other neuronal 
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populations.  In the heart GIRK4 interacts with GIRK1 to form the cardiac GIRK channel 
(IKACh) [157, 167]. The molecular differences between the various subunits regulate 
differences in expression and trafficking to the plasma membrane [167].  Only GIRK2 
and GIRK4 can form homomeric GIRK channels, as they contain an endoplasmic 
reticulum export motif [168-170].  GIRK1 and GIRK3 lack this motif so they must 
interact with GIRK2 or GIRK4 to leave the endoplasmic reticulum and form a functional 
channel at the plasma membrane [154, 168, 169, 171-174]. GIRK3 and GIRK2c, a splice 
variant of GIRK2, also contain a class I PDZ binding motif that allows them to interact 
with other proteins that contain a PDZ domain, such as sorting nexin 27 (SNX27)  [175, 
176].  GIRK3 also contains a lysosomal targeting sequence, which reduces GIRK3-
containing channel expression at the plasma membrane and total protein levels [168].   
C. Expression  
Neuronal GIRK channels are mainly expressed somatodendritically [177-179].  
Somatodendritic expression refers to GIRK channels found in perisynaptic regions of the 
soma and dendrites as well as in the dendritic shaft and spines, as demonstrated in various 
in situ hybridization and immunoelectron microscopic labeling experiments [160, 180-
182].  Although mostly postsynaptic, some presynaptic expression of GIRK channels has 
been observed in certain neuron populations [179, 183].  The three main mammalian 
GIRK subunits identified (GIRK1, GIRK2, and GIRK3) are expressed in a variety of 
brain regions.  Heteromeric channels comprised of GIRK1 and GIRK2 are the prominent 
GIRK channel in the brain [181, 184]. However, GIRK subunit expression depends on 
the brain region and cell type of interest [167, 185].  For example, in brain regions such 
as the mPFC and hippocampus GIRK1, GIRK2, and GIRK3 are expressed, making 
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several GIRK channel subunit combinations possible [185-187] (Figure 1.2).  DA 
neurons of the substantia nigra (SN) are unique in that they only express GIRK2 
homomeric channels [155, 185].  The two main cell types of the VTA have different 
GIRK subunit expression.  VTA GABA neurons express GIRK1, GIRK2, and GIRK3, 
making several GIRK channel subunit combinations possible [185-187] (Figure 1.2). 
However, DA neurons of the VTA only express GIRK2 and GIRK3 forming 
GIRK2/GIRK3 heteromeric channels [180, 188].  It has also been shown that in the 
absence of GIRK3 expression (Girk3-/-), functional GIRK2 homomeric channels can form 
(Figure 1.2).  Different GIRK channel subunit compositions have been linked to 
differences in GIRK channel functional properties, such as sensitivity to GPCR 
stimulation [185, 188, 189], but whether subunit composition was relevant to drug-
induced reward-related behavior required further investigation.  
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Figure 1.2. Inhibitory GPCR and GIRK channel subunit expression in the 
mesocorticolimbic DA system.  Inhibitory GPCR-GIRK signaling plays an important 
role in controlling cellular excitability of VTA DA and GABA neurons.  GABABR are 
found on both neuron populations (A, B). D2Rs are expressed on VTA DA neurons (B), 
while MORs are expressed on both DA and GABA neurons (A, B) of the VTA.  VTA 
GABA neurons (A) express GIRK1, GIRK2, and GIRK3 subunits, with the predominant 
GIRK channel likely containing GIRK1 and GIRK2 (GIRK1/GIRK2 heteromer).  VTA 
DA neurons express a GIRK2/GIRK3 heteromeric channel (B). Of note, both VTA 
neuron populations express GIRK2, allowing for the expression of GIRK2/GIRK2 
homomeric channels. 
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D. GIRK Channels and Addiction 
 GIRK channel activity is a key regulator of many central nervous system 
functions, such as processing of reward and pain signals, motor control, and cognition.  
Dysregulation of GIRK-dependent signaling is implicated in drug addiction, 
hyperalgesia, Parkinson’s disease and epilepsy, Down Syndrome, as well as depression, 
anxiety, attention deficit hyperactivity disorder (ADHD), and schizophrenia [165, 186, 
187, 190-194].  The relevance of GIRK-dependent signaling to drug addiction is 
supported by the fact that GPCR-GIRK signaling has been shown to play a role in both 
the cellular and behavioral effect of several drugs of abuse [195].  Different drugs of 
abuse work on a variety of molecular and cellular targets, yet most evoke overlapping 
behaviors, such as motor-stimulation, escalated drug-taking, and cue- or drug-induced 
relapse [74, 79, 165, 196].  Similarities in the drug-induced reward-related behaviors 
suggest a common neuronal/molecular pathway through which drugs of abuse work to 
produce reward and ultimately addiction [197, 198]. As GIRK channels regulate the 
cellular and reward-related behaviors associated with multiple drugs of abuse (e.g. 
gamma-Hydroxybutyrate (GHB), cocaine, opioids), they are one potential candidate 
[188, 195, 199, 200].  In this context, the exact mechanism(s) through which various 
drugs of abuse modulate GIRK activity and the relevance of GIRK channel subunit 
composition to the reward-related behavioral effect of drugs of abuse remains unclear.  
With further insights into the nuances of drug-induced adaptations of GPCR-GIRK 
signaling in the VTA, the development of new potential therapeutic targets for treating 
addiction may be possible.   
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V. DRUG-INDUCED ALTERATIONS TO INHIBITORY GPCR-GIRK 
SIGNALING 
i. Opioids: MOR-GIRK 
A. Pharmacology  
Opioid receptors are part of the GPCR family and can be divided into three 
subtypes mu (MOR), delta (DOR), and kappa (KOR) [201].  MORs are expressed in 
regions of the mesocorticolimbic DA system, the dorsal horn of the spinal cord, 
periaqueductal gray, and intestinal tract, and can be activated by many agonists including 
morphine, other prescription opioid pain relievers, and endogenous opioid compounds 
[202].  Opioid activation of MOR and subsequent modulation of downstream targets are 
thought to be responsible for producing both their desired analgesic effect as well as their 
undesired side effects, including tolerance and addiction [203]. These reward-related 
effects linked to activation of MOR are thought to arise from alterations to cellular 
signaling within the mesocorticolimbic DA system.  While the mechanisms through 
which opioids produce analgesia are well understood [204], further work is needed to 
improve our understanding of how opioid-induced changes in signaling within the 
mesocorticolimbic DA system contribute to opioid reward.  
MORs couple to the Gαi/o class of G proteins and modulate a number of 
downstream effectors [205].  The activated Gαi/o inhibits adenylyl cyclase, while free Gβγ 
inhibits voltage-gated Ca2+ channels and activates GIRK channels [205].  MORs are 
located at both presynaptic terminals and somatodendritic sites of various neurons.  
Presynaptic MOR activation inhibits voltage gated Ca2+ channels, leading to reduced 
Ca2+ entry and reduced neurotransmitter release [206-208]. Somatodendritic MOR 
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activation is thought to activate GIRK channels, resulting in hyperpolarization of the 
neuron [178, 209, 210]. Currently the importance of presynaptic versus somatodendritic 
MOR activation to the rewarding properties of opioids is currently not well-understood.  
B. Opioid Signaling in the VTA 
The VTA has been established as a critical anatomic substrate of opioid reward-
related behavior through studies involving intracranial lesion or pharmacology.  For 
example, chemical lesion of the VTA-NAc connection using 6-OHDA disrupts DA 
signaling between the VTA and NAc to successfully block heroin self-administration and 
opioid-induced locomotor activity [96]. Pharmacology studies show that rodents will 
work to self-administer opioid agonists directly to multiple brain regions, but self-
administration to the VTA can be established at lower doses than to adjacent 
mesocorticolimbic regions [93, 211].   In addition, opioid agonists infused into the VTA 
establish reward-related behaviors such as locomotor activity and conditioned place 
preference (CPP) [89, 212].  Thus, the VTA is critical to opioid-induced reward. 
Dogma in the opioid field has maintained that opioids exert their rewarding 
effects through alterations in VTA neuronal activity, and specifically enhanced activity of 
the VTA DA neurons [213]. This idea was substantiated by the work of Johnson and 
North in the early 1990s.  Their studies suggested that activation of MORs on VTA 
GABA neurons was responsible for the opioid-induced increase in extracellular DA and 
subsequent reward-related effects of opioids [83, 214].  More specifically, under normal 
conditions, the tonic release of GABA from VTA GABA neurons is able to inhibit VTA 
DA neurons and maintain a basal level of DA released to downstream targets, like the 
NAc.  However, when an opioid, such as morphine, is present there are a number of 
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changes to VTA neuronal activity.  When morphine is present, it activates MORs on 
VTA GABA neurons, resulting in the hyperpolarization of these neurons [214].  The 
MOR-induced activation of somatodendritic GIRK channels is thought to underlie this 
opioid-induced cellular hyperpolarization. These hyperpolarized GABA neurons then 
release less GABA on VTA DA neurons, resulting in the disinhibition of VTA DA 
neurons [215, 216].  The disinhibition of the VTA DA neurons then increases firing 
activity, leading to increased levels of DA release in downstream targets [217, 218].  
Although these changes in signaling have been shown, there are still many unanswered 
questions regarding the mechanism(s) of opioid actions within the VTA, specifically the 
contribution of MOR-GIRK signaling in VTA GABA neurons.  Furthermore, the 
relevance of MOR-GIRK signaling in VTA GABA neurons to opioid-induced reward-
related behaviors remains poorly understood. 
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Figure 1.3. Opioid-induced disinhibition of VTA DA neurons hypothesis.  The 
proposed model of opioid effects in the VTA suggested that under normal conditions (A) 
tonic VTA GABA neuron activity maintain a basal level of VTA DA neuron activity and 
DA release to downstream targets (mPFC/NAc).  (B) When opioids are present they 
activate MORs on VTA GABA neurons resulting in (1) VTA GABA neuron inhibition.  
Reduced GABA input results in (2) disinhibition of VTA DA neurons and increased DA 
levels in downstream targets.  
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ii.  Cocaine: GABABR-GIRK and D2R-GIRK 
A. Cocaine: Elevated Dopamine 
 Cocaine produces its euphoric and addictive effects mainly through its actions in 
the mesocorticolimbic DA system [219-221]. Following exposure, cocaine crosses the 
blood-brain barrier and produces a rapid increase in DA levels within the 
mesocorticolimbic DA system [219-221].  This increase in DA is achieved by cocaine 
binding to and blocking the DA reuptake transporter (DAT) found on DA neurons [222-
224].  By preventing DAT to transport DA out of the synaptic cleft and back into the 
presynaptic DA neuron terminal, more DA is present in the synapse allowing for 
continued activation of DA receptors [90, 225, 226].  In addition to elevated DA levels, 
cocaine exposure has been shown to trigger adaptations to both excitatory and inhibitory 
signaling within the mesocorticolimbic DA system.  Much of the recent research has 
focused on the acute alterations or persistent synaptic adaptions drugs of abuse produce 
in excitatory neurotransmission [80, 227].  Thus, there is still much to be learned about 
the molecular and functional mechanisms of drug-induced adaptations to inhibitory 
signaling, including signaling via GABABR and D2R, within the mesocorticolimbic DA 
system and the relevance of these adaptations to the reward-related behavior effects of 
cocaine.   
B.  Inhibitory Signaling: GABABR  
The GABABR is a Gαi/o-coupled GPCR that plays a key role in inhibitory 
neurotransmission.  Agonists for GABABR include the endogenous neurotransmitter 
GABA and drugs such as baclofen and GHB. GABABRs are expressed throughout the 
CNS, including the VTA and mPFC. Somatodendritic GABABR activation results in 
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cellular hyperpolarization through activation of GIRK channels throughout the CNS 
[178].  Expression and activity of the GABABR can be altered by exposure to drugs of 
abuse, such as psychostimulants [187, 199, 228].  
a. VTA 
Cocaine-induced adaptations in GABABR-mediated inhibitory signaling can be 
found in both VTA GABA and DA neurons.  For example, a single injection of cocaine is 
sufficient to trigger the suppression of GABABR-GIRK signaling in VTA DA and GABA 
neurons [199, 229].  In VTA DA neurons, this adaptation persists up to 4-7 days 
following cocaine exposure and is correlated with enhanced AMPAR-mediated current 
[128, 199].  Accompanying this cocaine-induced reduction in inhibitory signaling is a 
reduction in GIRK2 expression at the plasma membrane [199].  Repeated cocaine 
exposure results in a similar reduction in GABABR-GIRK signaling in VTA DA neurons, 
as well as cocaine-induced behavioral sensitization [199]. This data suggests that acute 
and repeated cocaine exposure triggers a reduction in GABABR-GIRK signaling in VTA 
DA neurons, and that GABABR-GIRK signaling in VTA DA neurons plays a role in the 
motor-stimulatory effects of cocaine.  
b. mPFC 
 GABABR-GIRK signaling in the mPFC plays a key role in modulating reward-
related behavior and is reduced by repeated cocaine exposure [187].  Accompanying this 
cocaine-induced reduction in GABABR-GIRK signaling is a reduction in GABABR and 
GIRK2 expression at the plasma membrane.  Infusion of the GABABR agonist baclofen 
into the mPFC prior to cocaine exposure completely blocks the ability of cocaine to 
increase locomotor activity and induces behavioral sensitization [230]. Interestingly, 
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prior experience with repeated cocaine prevents these effects of baclofen on reward-
related behavior [231, 232].  Additionally, baclofen infusion into the mPFC of cocaine-
treated animals enhances glutamate release to the VTA and NAc, with opposite effects 
observed in drug-naïve animals [231].  Importantly, such increases in mPFC output to the 
VTA and NAc are thought to be responsible for the effects of psychostimulants and other 
drugs of abuse on reward-related behaviors, including locomotor sensitization, drug-
taking behavior, and cue- or drug-induced relapse [80, 114, 118].  Collectively, these 
findings suggest that cocaine impairs GABABR-dependent signaling in the VTA and 
mPFC, and these changes contribute to the cocaine-induced reward-related behaviors. 
C. Inhibitory Signaling: D2R  
The D2R is a Gαi/o G protein GPCR that plays a key role in inhibitory 
neurotransmission [150].  Agonists for D2R include the endogenous neurotransmitter DA 
and drugs, such as quinpirole.  D2Rs are expressed throughout the CNS and are found on 
neurons within the VTA, both at presynaptic and somatodendritic locations. 
Somatodendritic D2R activation results in neuronal hyperpolarization through activation 
of GIRK channels [233, 234].  Similar to GABABR, the expression and activity of the 
D2R can be altered by exposure to drugs of abuse, such as psychostimulants including 
cocaine.  DA activation of the somatodendritic D2Rs on VTA DA neurons represents a 
key autoinhibitory feedback pathway that attempts to restore the activity of VTA DA 
neurons and extracellular DA concentration [233].  Genetic ablation or pharmacologic 
inhibition of this D2R autoinhibitory feedback pathway results in altered cellular and 
behavioral responses to cocaine [235-237].   
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a. VTA 
D2Rs are located somatodendritically, on the soma and dendrite, on VTA DA 
neurons and are activated by cocaine-induced extracellular release of DA in the VTA 
[238, 239].  Cocaine produces bidirectional changes in the firing rate of VTA DA 
neurons based on acute or repeated cocaine exposure.  These somatodendritic D2Rs work 
to decrease DA neuron firing rates as an autoinhibitory pathway to counteract the 
increase of DA caused by acute cocaine, likely through activation of GIRK channels 
[150, 199, 239].  In contrast, repeated cocaine exposure causes a temporary increase in 
firing rate that can reset shortly (<10 days) following withdrawal [240-242].  This 
persistent cocaine-induced increase in mesocorticolimbic DA transmission is correlated 
with a reduction in D2R autoreceptor function on VTA DA neurons.  Acute 
pharmacologic stimulation of D2R in the VTA also reduces D2R autoreceptor function on 
VTA DA neurons [243].  In addition to these in vitro studies showing D2R-dependent 
signaling is weakened by repeated cocaine, imaging studies have shown that human 
cocaine addicts have reduced D2R expression in parts of their mesocorticolimbic DA 
system [244].   Collectively, these findings suggest that D2R signaling in VTA DA 
neurons is vital to the molecular adaptations triggered by cocaine exposure, and that 
cocaine-induced changes in D2R-dependent signaling in the VTA may contribute to 
cocaine-induced reward-related behaviors.  
 
VI. Purpose of Studies 
Drug addiction represents a costly financial and social burden to society. Current 
available treatments for substance abuse are limited, largely ineffective, and produce 
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many undesirable side effects.  In order to identify novel therapeutic targets and improve 
pharmacotherapy, a better understanding of the molecular and cellular processes involved 
in addiction is required. While drug induced adaptations to excitatory signaling within the 
mesocorticolimbic DA system have been well characterized, the adaptations and 
importance of inhibitory signaling requires further investigation.  The goal of these 
dissertation studies was to enhance our understanding of the role of G protein dependent 
inhibitory signaling throughout the mesocorticolimbic DA system, and how it mediates 
the cellular and behavioral effect of drugs of abuse.  
 In this work, I investigated the role of GIRK channels in the VTA using a 
number of pharmacologic and genetic tools.  It is important to note, that although several 
compounds directly modulate the activity of GIRK channels, they lack specificity and act 
on several other types of potassium channels.  Barium (Ba2+) and tertiapin (TPN) are two 
widely used GIRK channel antagonists [245-247]. However, the low potency and lack of 
selectivity make results of studies utilizing these compounds difficult to interpret [166, 
245, 248, 249].  This lack of selective pharmacology has pushed the majority of GIRK 
channel research to utilize genetic approaches, such as knockout mice and targeted viral 
manipulations [190, 209, 250].  The generation of Girk-/- mice involved the removal of 
the N-terminus, membrane-spanning domains, the pore regions, and most of the C-
terminus, resulting in a constitutive loss of the specific GIRK subunit expression.  One 
limitation of constitutive ablation of a gene is that compensatory genetic adaptations can 
occur, such as upregulation/downregulation of other genes.  These compensatory 
adaptations can mask phenotypes and make results difficult to interpret. 
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 To gain a more refined understanding of the importance of GIRK-dependent 
signaling in drug-induced reward-related behavior, and the associated underlying cellular 
mechanisms, we generated a conditional knockout mouse line targeting GIRK2 
(Girk2flox/flox).  The “floxing” of a gene allows for Cre recombinase to selectively remove 
the gene of interest [251].  The generation of the Girk2flox/flox line gave us the ability to 
manipulate GIRK2-dependent signaling in specific neuron populations by crossing this 
line with various neuron-specific Cre-driver lines (DA neurons (DATCre) and GABA 
neurons (GADCre)). This novel approach used throughout my dissertation research 
afforded selective and conditional knockdown of GIRK-dependent signaling, in turn 
providing valuable insight into the relevance of GPCR-GIRK signaling to the molecular 
and behavioral effects of drugs of abuse.  The work in Chapter 2 is focused on the 
cellular and behavioral effects of opioids on signaling within the VTA and the relevance 
of GIRK channel function to opioid-induced locomotor activity. Chapter 3 is focused on 
G protein-dependent inhibitory signaling in VTA DA neurons and its relevance to the 
reward-related behavioral effects linked to cocaine. Together the findings of these studies 
demonstrate that inhibitory signaling through GPCR-GIRK signaling in neurons of the 
VTA is critical to the molecular and behavioral effects of drugs of abuse.  
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CHAPTER 2 
 
GIRK channels modulate opioid-induced motor activity in a 
cell type- and subunit-dependent manner 
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Introduction 
The dopamine (DA) projection from the ventral tegmental area (VTA) to the nucleus 
accumbens (NAc) is a critical anatomic substrate for drug-induced exploratory/seeking 
behavior (motor activation) and an associated anticipatory state comparable to ‘wanting’ 
[225, 252, 253]. Neuroadaptations within this pathway underlie the development and 
expression of behavioral sensitization and drug seeking associated with repeated drug 
administration [252, 254, 255]. Opioids enhance VTA DA neuron activity [216], leading 
to increased DA levels and neuronal activation in the NAc, which in turn augments motor 
activity [256-259]. The relevance of the opioid-induced increase in DA 
neurotransmission is underscored by the inhibitory impact of DA receptor antagonists 
and intra-NAc DA depletion on opioid-induced motor activity [88, 260, 261], and the 
lack of morphine-induced motor activation in DA-deficient mice [262].  
The motor-stimulatory and associated neurochemical effects of opioids are dependent 
on the mu opioid receptor (MOR) [218, 263-265]. MOR activation has been proposed to 
inhibit GABA neurons that dampen the output of VTA DA neurons (disinhibition), 
leading to increased DA neurotransmission [214]. Indeed, VTA DA neurons in the rat 
receive opioid-sensitive input from GABA neurons in the VTA and rostromedial 
tegmental nucleus (RMTg) [266, 267]. Both pre- and postsynaptic mechanisms have been 
proposed to mediate the inhibitory impact of opioids on midbrain GABA 
neurotransmission [214, 266-268], though their relative significance to the cellular and 
behavioral effects of opioids remains unclear.  
The postsynaptic inhibitory effect of opioids on GABA neurons is thought to involve 
activation of G protein-gated inwardly-rectifying K+ (GIRK/Kir3) channels [196, 214]. In 
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support of this contention, loss of GIRK1 or GIRK2 correlates with diminished opioid 
inhibition of locus coeruleus and spinal cord neurons [209, 269], and blunted intrathecal 
morphine and DAMGO analgesia [270, 271]. Moreover, loss of GIRK2 correlates with 
diminished systemic morphine-induced analgesia [191], and ablation of GIRK channels 
in the locus coeruleus precludes the induction of opioid dependence [186]. 
Here, we sought to determine whether and how GIRK channels contribute to opioid-
induced motor activation. Our working hypothesis was that opioids inhibit midbrain 
GABA neurons in a GIRK-dependent manner, leading to disinhibition of VTA DA 
neurons and an associated increase in motor activity. Using novel mutant mice and 
pharmacological tools, however, we found that GIRK channel activation in GABA 
neurons plays little role in opioid-induced motor activity. Instead, our data suggest that 
the GIRK channel in VTA DA neurons modulates the sensitivity to the motor-stimulatory 
effects of opioids in mice. 
 
Materials and Methods 
Animals.  
Animal experimentation was reviewed and approved by the Institutional Animal 
Care and Use Committee at the University of Minnesota. Generation of constitutive Girk–
/– mice was described previously [190, 209, 250]. GAD67-eGFP mice [272] and Pitx3-
eGFP mice [273] were generously provided by Drs. T. Kaneko and Meng Li, 
respectively. Gad2tm2(cre)Zjh/J (GAD-Cre), B6.SJL-Slc6a3tm1.1c\(cre)Bkmn/J (DAT-Cre), and 
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). 
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Girk2flox/flox mice were generated under contract by InGenious Targeting Labs 
(Ronkonkoma, NY). 
Drugs.  
DAMGO, naloxone, and baclofen were purchased from Sigma (St. Louis, MO). 
CGP54626 was purchased from Tocris (Bristol, UK).  rTertiapin-Q (TPN) and GIRK2 
antibody were purchased from Alomone Labs (Jerusalem, Israel). Morphine was 
purchased from Boynton Pharmacy (University of Minnesota). ML297 was synthesized 
in the Vanderbilt Institute of Chemical Biology Chemical Synthesis Core and Vanderbilt 
MLPCN Specialized Chemistry Center.  
Generation of Girk2flox/flox mice.  
The mouse Girk2 gene (also known as Kcnj6; Gene ID 16522) consists of at least 
7 exons and spans ~250 kbp on the reverse strand of chromosome 16 (94,749,266-
94,997,696). Several alternative splice variants have been identified that utilize 1 of 2 
potential translation start sites [274]. Exon 4 was targeted, as it is present in all known 
Girk2 splice variants, and because it contains coding sequence for key functional 
domains of the GIRK2 protein. A C57BL/6 BAC clone (RP23: 155F22) containing Girk2 
exon 4 and surrounding sequence was identified and used to generate the targeting 
construct. The targeting construct was validated by sequencing, linearized, and 
electroporated into iTL BA1 (C57BL/6 x 129/SvEv) hybrid embryonic stem cells. 
Neomycin-resistant clones (400) were screened by PCR, which identified 5 candidate 
clones that were amplified, re-analyzed by PCR, and evaluated by Southern blotting for 
proper integration of the targeting construct (including both 5’ and 3’ homology arms); 3 
of these 5 clones harbored a properly-targeted Girk2 allele. Two ES clones (#152 and 
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#364) were then micro-injected into C57BL/6 blastocysts, resulting in 7 chimeras 
exhibiting a high percentage of agouti coat color. These mice were mated to C57BL/6N 
flippase (Flp) deleter mice (C57BL/6-Tg(ACTFLPe)) to remove the NEO cassette. Two 
F1 offspring (deriving from ES clone #364) were identified that lacked the NEO cassette, 
but did contain intact 5’ and 3’ homology arms and loxP sites (as assessed by PCR and 
DNA sequencing). These mice, which were heterozygous for the conditional mutant 
allele (Girk2flox/wt), were then backcrossed with C57BL/6J mice to amplify the colony. 
Resulting Girk2flox/wt offspring were then inbred to produce mice homozygous for the 
Girk2flox allele (Girk2flox/flox mice). 
Quantitative RT-PCR.  
Punches (2-mm diameter, 2-mm thick) from the cortex and hippocampus, and half 
of the cerebellum, were taken from wild-type and Girk2flox/flox siblings (7-10 wk). 
Punches were frozen on crushed dry ice and stored at -80°C. Total RNA of cortex and 
hippocampus was isolated using the RNeasy Plus MicroTM Kit (Qiagen; Valencia, CA). 
Total RNA from the cerebellum was isolated using TRIzol (InvitrogenTM, Life 
Technologies; Grand Island, NY) according to manufacturer's recommendations, and 
treated with recombinant DNase I (Roche; Indianapolis, IN). Reverse transcription was 
performed using an iScriptTM cDNA synthesis kit (Bio-Rad; Hercules, CA). Quantitative 
PCR was performed on a LightCycler® 480 II system in a final volume of 20 µL with a 
LightCycler® 480 SYBR Green I Master kit (Roche). After pre-incubation at 95°C for 5 
min, amplification consisted of 45 cycles of denaturation for 10 s at 95°C, followed by 
annealing for 30 s at 60°C and extension for 10 s at 72°C. qRT-PCR oligonucleotide 
sequences for GIRK2 are as follows: GIRK2(forward) – 5’-
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CGTGGAGTGAATTATTGAATCT-3’ and GIRK(reverse) - 5’-
GTCATTTCTTCTTTGTGCTTTT-3’. GAPDH mRNA levels were used for 
normalization purposes using GAPDH QuantiTect oligonucleotides (Qiagen). Samples 
were analyzed using the 2[ΔCt] method [275]. 
Quantitative immunoblotting.  
Punches (2-mm diameter, 2-mm thick) of defined brain regions were taken from 
wild-type and Girk2flox/flox siblings (7-10 wk). Samples were sonicated in 1% SDS lysis 
buffer containing a Halt phosphatase and protease inhibitor cocktail (Thermo Fisher 
Scientific Inc.; Waltham, MA), heated at 85ºC for 10 min, and centrifuged at 4ºC for 20 
min at 16,000xg. Protein samples (40 µg) were then separated by SDS-PAGE and 
transferred to nitrocellulose membranes. Membranes were blocked in 5% milk/PBS, 
incubated overnight at 4°C with antibodies against GIRK2 (1:200; Alomone Labs) or β-
actin (1:10,000; Abcam; Cambridge, MA), and diluted in 5% milk/PBS/0.1% Tween-20. 
Membranes were washed with PBS/0.1% Tween-20 and incubated with donkey anti-
rabbit (926-68072; 1:5000; LI-COR Biosciences; Lincoln, NE) or donkey anti-mouse 
(926-32212; 1:1000-5000; LI-COR) secondary antibodies. Blots were developed using 
the Odyssey infrared imaging system (LI-COR), and the integrated density of each band 
was measured using ImageJ software (NIH; Bethesda, MD). 
Immunohistochemistry.  
Mice (7-10 wk) were given a euthanizing dose of ketamine/xylazine (250 and 25 
mg/kg i.p., respectively) and perfused transcardially with Ca2+-free Tyrode’s solution 
followed by 4% paraformaldehyde containing 14% picric acid. Brains were post-fixed 
overnight in Sorenson’s Buffer containing 10% sucrose at 4˚C. Tissue was sectioned 
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coronally at 12 µm by cryostat and mounted to slides. Sections containing the VTA were 
washed in TBS for 10 min, and then placed in boiling citric acid (10 mM; 30 min).  
Slides were then washed in TBS (3 x 5 min), and incubated for 1 h in TBS blocking 
solution containing casein, Tween-20, and Triton X-100 (all at 0.2%). Sections were 
exposed to rabbit anti-GIRK2 antibody (1:1000; Alomone labs) diluted in TBS solution 
containing casein and Tween-20 (both 0.2%) overnight, at room temperature in a 
humidity chamber. The following day, sections were washed in TBS (3 x 20 min) and 
then incubated for 2 h in donkey anti-rabbit IgG Cy3 secondary antibody (1:500; Jackson 
Immunoresearch Laboratories, Inc.; West Grove, PA) diluted in TBS containing casein 
and Tween-20 (both at 0.2%). Sections were washed in TBS (3 x 20 min), dehydrated 
through a series of graded alcohols, cleared in xylene, and coverslipped with DPX 
(Thermo Fisher Scientific Inc.). Fluorescence was visualized with an IX81ZDC2 
Olympus microscope with disk-scanning unit and imaged with MetaMorph Advanced 
software. Digital images were colorized with ImageJ 64 software and prepared for 
micrographic presentation in Adobe Illustrator and Photoshop 6 (Adobe Systems, Inc.); 
no adjustments were made to saturation, brightness or contrast.   
Slice electrophysiology.  
Coronal and horizontal slices from wild-type and mutant mice (4-10 wk) were 
prepared as described [199]. VTA neurons found in the lateral aspect of the VTA, near 
the medial terminal nucleus of the accessory optic tract, were targeted for analysis. Upon 
achieving whole-cell access, the current response to a 1-s voltage ramp (-60 to -120 mV) 
was used to measure Ih presence and amplitude and spontaneous activity (I=0) was 
assessed. For rheobase measurements, cells were held in current-clamp at 0 pA to obtain 
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resting membrane potential and then progressively-increasing current pulses (1-s 
duration) were applied until the cell fired an action potential. Changes in somatodendritic 
holding current evoked by baclofen, DAMGO, or ML297 were measured at a holding 
potential of -60 mV, as described [199].  
Some studies involved targeted evaluation of VTA DA and GABA neurons, as 
defined by eGFP expression in VTA neurons from Pitx3-eGFP and GAD67-eGFP mice, 
respectively [272, 273]. For other studies, we relied on morphological and functional 
criteria to identify “putative” VTA GABA and DA neurons. Specifically, small (apparent 
capacitance <40 pF) VTA neurons exhibiting little or no Ih current (<35 pA) were 
identified as putative GABA neurons, as these properties were typical of eGFP-positive 
VTA neurons from GAD67-eGFP mice [180]. Larger (apparent capacitance >50 pF) 
VTA neurons exhibiting substantial Ih current (>100 pA) were identified as putative DA 
neurons, as these properties correlated well with tyrosine hydroxylase expression [188, 
199], and because this was a typical profile for eGFP-positive VTA neurons in slices 
from Pitx3-eGFP mice [180].  
Morphine-induced motor activity.  
 Systemic morphine-induced locomotor activity assessments were performed as 
described [276]. Subjects (6-12 wk) were handled and acclimated to the testing room for 
1 h prior, followed by habituation to activity chambers and systemic injections (saline, 
i.p.), on each of the 3 days preceding testing. Total distance traveled during the 60-min 
period following saline injection on the last acclimation day was defined as the response 
to 0 mg/kg morphine. Subjects were then given an ascending series of systemic morphine 
doses (3, 10, 30 mg/kg i.p.), with doses separated by 3-d intervals.  
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Intracranial manipulations.  
Mice (6-8 wk) were anesthetized with ketamine and xylazine (100 and 10 mg/kg, 
i.p.) and placed in a stereotaxic frame (David Kopf Instruments; Tujunga, CA). For 
intracranial pharmacology studies, bilateral stainless steel guide cannulae (Plastics One 
Inc.; Roanoke, VA) targeting the VTA (-3.08 mm AP, ±0.5 mm ML, -3.5 mm DV) or 
RMTg (-3.90 mm AP, ±0.5 mm ML, -3.4 mm DV) were implanted 1 mm above the 
infusion target. Cannulae were held in place by stainless steel mounting screws (0-80 x 
3/32; Plastics One) and dental acrylate (Henry Schein; Melville, NY), with stylets 
inserted following surgery to prevent blockage. Mice were allowed to recover for 7-9 d 
prior to behavioral testing. 
On day 1 of testing, mice were gently restrained (mimicking the injection procedure) 
and placed in the open-field chamber. On day 2, mice were restrained, and then dummy 
cannulae were removed and replaced with injection cannulae attached to the delivery 
system. On day 3, mice were given infusions (0.5 µL/side/min) of vehicle (saline or 
saline/DMSO) or drug (DAMGO or ML297) using a KSD230 multi-channel syringe 
pump controller (KD Scientific Inc.; Holliston, MA).  Injection cannulae consisted of 20-
mm 33-GA stainless steel hypodermic tubes inserted into a 9-mm 26-GA segment in 
order to protrude 1 mm beyond the tip of the 10-mm guide cannula. Drug was delivered 
via catheter lines connected to a 10 µL Hamilton syringe. After infusion, injection 
cannulae were held in place for an additional 1-2 min to ensure proper drug diffusion. 
Thereafter, subjects were placed in the motor activity monitoring units for 60 min. Guide 
cannulae placement was assessed by post-hoc histology.  
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For the viral GIRK3 reconstitution study, cDNAs for yellow fluorescent protein 
(YFP) fused to mouse GIRK3, or green florescent protein (GFP) alone as a control, were 
sub-cloned into a CaMKII-pBOB 3rd-generation self-inactivating lentiviral vector (kindly 
provided by Dr. Inder Verma). Lentivirus was produced by the Gene Transfer, Targeting, 
and Therapeutics Core at The Salk Institute for Biological Studies. Viral titer was ~8 x 
109 TU/mL as determined by real-time PCR of infected 293T cells. GIRK3-YFP or 
control lentivirus were injected into the VTA (-3.08 mm AP, ±0.5 mm ML, -4.4 mm DV) 
of male mice (6-7 wk) using a 5 µL Hamilton syringe. Following infusion (0.5 µL/site; 
0.5 µL/min), the syringe was left in place for 10 min to reduce backflow. Systemic 
morphine-induced motor activity was evaluated 21 d after viral infusion, and only data 
from mice with confirmed viral expression in the VTA were analyzed. 
Statistical analysis.  
Data are presented throughout as the mean ± SEM. Statistical analyses were 
performed using Prism 6 (GraphPad Software, Inc.; La Jolla, CA) and SigmaPlot 11.0 
(Systat Software, Inc.; San Jose, CA). Unless specifically noted, male and female mice 
were used for all studies. No sex differences were observed for any measured parameter, 
and thus, data from male and female mice were pooled to increase statistical power. 
Electrophysiological data and motor activity data were analyzed with a Student’s t test, 
one-way or two-way ANOVA, or two-way repeated measures ANOVA followed by 
individual comparisons using the Bonferroni post-test method. For all statistical 
comparisons, differences were considered significant if P<0.05. 
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Results 
Morphine-induced motor activity in Girk–/– mice 
We began by evaluating the impact of constitutive Girk subunit ablation on systemic 
morphine-induced motor activity. Since ablation of either Girk1 or Girk2 correlated with 
diminished opioid analgesia [191, 270, 271], and since Girk2 ablation correlated with 
decreased opioid-induced hypothermia [277], we predicted that mice lacking GIRK1 
and/or GIRK2 would exhibit diminished systemic morphine-induced motor activity. 
Surprisingly, however, the motor-stimulatory effect of systemic morphine was enhanced 
in Girk2–/– mice at the higher doses tested (10 and 30 mg/kg; Fig. 2.1). Girk1–/– mice also 
showed increased morphine-induced activity, but only at the highest morphine dose. 
Thus, GIRK channels modulate systemic morphine-induced motor activity, but in a 
manner inconsistent with their predicted role as proximal mediators of the underlying 
opioid-induced signaling. 
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Figure 2.1. Constitutive Girk subunit ablation and morphine-induced motor activity. 
Total distance traveled by adult male wild-type (white; n=26/dose), Girk1–/– (gray; 
n=18/dose), and Girk2–/– (black, n=7/dose) mice during a 60-min test following systemic 
administration of saline (0) or morphine (3, 10, 30 mg/kg i.p.). Main effects of genotype 
(F(2,48)=12.8, P <0.0001) and dose (F(3,144)=133.6, P<0.0001) were observed, as well as a 
significant interaction between genotype and dose (F(6,144)=5.4, P<0.0001). Symbol: 
***P<0.001 vs. wild-type (within dose). 
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Morphine-induced motor activity in mice lacking GIRK channels in GABA neurons 
GIRK channel activation in GABA neurons has been implicated in the opioid-induced 
disinhibition of VTA DA neurons and associated behavior [196, 214]. Global and 
constitutive GIRK subunit ablation, however, may impact excitability in multiple cell 
types that exert opposing influence on morphine-induced motor activity [228]. To 
evaluate the impact of selective ablation of GIRK channels in GABA neurons on 
morphine-induced motor activity, we generated conditional Girk2–/– (Girk2flox/flox) mice 
(Fig. 2.2A-C). After determining that Girk2flox/flox mice exhibited normal levels of GIRK2 
mRNA and protein in multiple brain regions (Fig. 2.2D,E), we crossed Girk2flox/flox mice 
with Gad2tm2(cre)Zjh/J (GAD-Cre) mice, which express Cre recombinase under the control 
of the Gad2 promoter. Cre recombinase-driven reporter expression in GAD-Cre mice is 
observed throughout the brain, but is restricted to GABA neurons [278].  
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Figure 2.2. Generation of Girk2flox/flox mice. (A) Depiction of the mouse Girk2/Kcnj6 
gene, highlighting the 7 known exons (rectangles with corresponding numbers below) 
[274]. While several alternative splice variants have been identified, utilizing two distinct 
translation initiation codons (ATG) and four distinct translation stop codons (TGA), all 
known variants contain exon 4. Shaded regions of exons denote protein-coding sequence. 
Some exons (1, 4, and 6) contain internal splice acceptor sites, denoted by vertical lines. 
(B) Schematic depictions of a GIRK2 subunit. The image on the left shows the 
membrane topology of a GIRK2 subunit. Each subunit contains intracellular N- and C-
terminal domains, 2 membrane spanning domains (M1 and M2), 2 extracellular loops (x1 
and x2), and a pore domain (P). The schematic on the right is a linear depiction of the 
GIRK2a subunit, a prominent isoform in the brain [274]. The region encoded by exon 4, 
which includes most of the N-terminus/NT, both membrane-spanning domains and 
extracellular loops, the pore domain, and much of the C-terminus/CT, is denoted by 
arrows. (C) The Girk2 targeting strategy included engineering a loxP site just upstream 
(214 bp) of exon 4 and incorporating a neomycin (NEO) resistance cassette containing 
flippase (Flp) recognition target (FRT) sites and a second loxP site; this cassette was 
positioned 795 bp downstream from exon 4. In total, the target region spanned 1.93 Kbp, 
and was flanked by a 5’ homology arm (extending ∼5.4 Kbp upstream from exon 4), and 
a 3’ homology arm (a ~7 Kbp fragment found immediately downstream from the target 
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region). The NEO cassette was removed crossing selected chimeras with C57BL/6N Flp 
deleter mice, yielding the Girk2flox allele. (D) Tissue from the cortex (n=9-10/genotype; 
t(17)=0.09, P=0.9), hippocampus (n=6-7/genotype; t11=0.4, P=0.7), and cerebellum (n=7-
8/genotype; t(13)=1.3, P=0.2) of wild-type and Girk2flox/flox (f/f) mice were evaluated for 
GIRK2 mRNA levels using quantitative RT-PCR. (E) GIRK2 protein immunoreactivity 
(ir) relative to β-­‐actin in samples from the cortex (n=6-7/genotype; t(11)=0.4, P=0.7), 
hippocampus (n=5-7/genotype; t(10)=0.05, P=1.0), and cerebellum (n=4-7/genotype; 
t(9)=0.6, P=0.6) of wild-type and Girk2flox/flox (f/f) mice were assessed using quantitative 
immunoblotting. The level of GIRK2, which is seen as a doublet (top panel), was 
compared to the level of β-actin control (bottom panel) in each sample. Gel images of 
GIRK2 and β-actin were cropped and aligned with a molecular weight scale showing the 
markers for 52 and 38 kDA. 
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To assess the functional impact and cell-type specificity of GIRK channel ablation in 
GAD-Cre:Girk2flox/flox mice, we measured somatodendritic currents evoked by the 
GABAB receptor agonist baclofen in putative GABA and DA neurons of the VTA. 
Previous work has shown that baclofen-induced currents in these two neuron populations 
are mediated in large part by GIRK2-containing channels [180, 188]. As predicted, 
baclofen-induced currents in putative VTA DA neurons were comparable in slices from 
GAD-Cre(+):Girk2flox/flox and GAD-Cre(-):Girk2flox/flox mice (Fig. 2.3A,B). In contrast, 
currents in putative VTA GABA neurons were significantly smaller in slices from GAD-
Cre(+):Girk2flox/flox mice as compared to GAD-Cre(-):Girk2flox/flox controls (Fig. 2.3C,D). 
Despite the loss of GIRK channels in putative GABA neurons in GAD-
Cre(+):Girk2flox/flox mice, no difference in systemic morphine-induced motor activity was 
observed between these mice and GAD-Cre(-):Girk2flox/flox controls (Fig. 2.3E).  
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Figure 2.3. GABA neuron-specific ablation of GIRK channels and morphine-
induced motor activity. (A) Representative traces of currents evoked by baclofen (Bac, 
200 µM) in putative VTA DA neurons from GAD-Cre(-):Girk2flox/flox (black) and GAD-
Cre(+):Girk2flox/flox (gray) mice. Currents were reversed by the GABAB receptor 
antagonist CGP54626 (CGP, 2 µM). Scale bars: 60 pA/200 s. (B) Summary plot of 
baclofen-induced currents in putative VTA DA neurons from GAD-Cre(-):Girk2flox/flox 
(white; n=7) and GAD-Cre(+):Girk2flox/flox (gray; n=8) mice. No genotype-dependent 
difference was observed (t(13)=0.09, P=0.9). (C) Representative traces of currents evoked 
by baclofen (Bac, 200 µM) in putative VTA GABA neurons from GAD-Cre(-
):Girk2flox/flox (left, black) and GAD-Cre(+):Girk2flox/flox (right, gray) mice. Scale bars: 20 
pA/200 s. (D) Summary plot of baclofen-induced currents in putative VTA GABA 
neurons from GAD-Cre(-):Girk2flox/flox (white; n=6) and GAD-Cre(+):Girk2flox/flox (gray; 
n=5) mice. A significant genotype-dependent difference was observed (t(9)=4.1, P<0.01). 
(E) Total distance traveled (in m) by GAD-Cre(-):Girk2flox/flox (white; n=14) and GAD-
Cre(+):Girk2flox/flox (gray; n=7) mice during a 60-min period following systemic (i.p.) 
administration of saline (0) or morphine (3, 10, 30 mg/kg). A main effect of dose 
(F(3,57)=76.6, P<0.0001) was observed, but there was no main effect of genotype 
(F(1,19)=0.02, P=0.9), nor was there an interaction between genotype and dose (F(3,57)=0.3, 
P=0.8).  
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Impact of GIRK channel manipulations on intracranial DAMGO-induced activity 
VTA DA neurons express a unique GIRK channel subtype (GIRK2/GIRK3 
heteromer), while single-cell RT-PCR analysis suggests that VTA GABA neurons may 
express GIRK1, GIRK2, and GIRK3 (Fig. 2.4A) [180, 188]. To test this proposal 
directly, we characterized GIRK channel activity in VTA GABA neurons. In slices from 
wild-type mice, baclofen (200 µM) reliably evoked an outward (inhibitory) current in 
putative VTA GABA neurons (Fig. 2.4B). Bath application of the non-selective K+ 
channel blocker Ba2+ (0.3 mM) or the GIRK channel blocker rTertiapin-Q (TPN, 200 
nM) blunted baclofen-induced currents (50-60%) in these neurons (Fig. 2.4C). Baclofen-
induced currents in putative VTA GABA neurons from Girk1–/– or Girk2–/– mice (but not 
Girk3–/– mice) were attenuated relative to controls, and were comparable in magnitude to 
currents measured in wild-type neurons in the presence of GIRK channel blockers (Fig. 
2.4C).  
To test whether GIRK1-containing channels mediate the MOR-dependent inhibition of 
VTA GABA neurons, we measured somatodendritic currents evoked by the MOR agonist 
DAMGO. Outward currents evoked by DAMGO (3 µM) and reversed by naloxone (10 
µM) were observed in only a subset (4/15) of VTA GABA neurons (Fig. 2.4D,E). None 
of the putative VTA GABA neurons from Girk1–/– mice (0/13) displayed an evident 
DAMGO-induced current (Fig. 2.4E), supporting the contention that GIRK1-containing 
GIRK channels mediate the direct inhibitory effect of MOR agonists on a subset of VTA 
GABA neurons.   
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Figure 2.4. Characterization of the GIRK channel in VTA GABA neurons. (A) 
Proposed GIRK subunit and receptor expression patterns in VTA DA and GABA 
neurons. (B) Typical current induced by baclofen (200 µM) and reversed by CGP54626 
(CGP, 2 µM) in a putative VTA GABA neuron from a wild-type mouse. Scale bars: 5 
pA/120 s. (C) The impact of pharmacologic and genetic ablation of GIRK channels on 
baclofen-induced currents in putative VTA GABA neurons (F(5,58)=12.5; P<0.0001). 
Currents are plotted for putative VTA GABA neurons from wild-type mice in the 
absence (control; n=21) or presence of external Ba2+ (0.3 mM; n=8) or rTertiapin-Q 
(TPN, 200 nM; n=4), and in neurons from Girk1–/– (red; n=9), Girk2–/– (gray; n=14), and 
Girk3–/– mice (gray; n=8). Symbols: *,*** P<0.05 and 0.001, respectively, vs. control. 
(D) Responses of two VTA GABA neurons (eGFP-positive VTA neurons in slices from 
GAD67-eGFP mice) to a saturating concentration of DAMGO (3 µM). The response 
observed in the neuron shown on the left was reversed by naloxone (Nal, 10 µM). Scale 
bars: 5 pA/120 s. (E) Summary of DAMGO-induced currents in putative VTA GABA 
neurons from wild-type (4/15 responders; 28.6 ± 2.7 pA) and Girk1–/– (0/13 responders) 
mice. Approximately one-third (4/15) of putative VTA GABA neurons evaluated 
exhibited a response to DAMGO (defined as a naloxone (Nal)-reversible current of >15 
pA); none of the neurons in slices from Girk1–/– mice exhibited a response to DAMGO. 
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Since Girk1 ablation should alter GIRK channel activity in VTA GABA but not VTA 
DA neurons, we next compared the motor activity evoked by infusion of DAMGO into 
the VTA of wild-type and Girk1–/– mice. Intra-VTA DAMGO increased motor activity in 
wild-type mice, with the maximal response observed at 1 nmol (Fig. 2.5A,B). The motor-
stimulatory effect of intra-VTA DAMGO was completely preserved in Girk1–/– mice. 
Administration of DAMGO to the adjacent RMTg also evoked increased motor activity 
in wild-type mice, in a dose-dependent manner, with peak response observed at the 0.1 
nmol dose (Fig. 2.5C,D). Intra-RMTg opioid-induced motor activity was not reduced in 
Girk1–/– mice. Rather, elevated motor activity was seen in Girk1–/– mice at the two 
highest doses tested. These findings argue that GIRK channel activation in midbrain 
GABA neurons is not required for opioid-induced motor activity.  
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Figure 2.5. Intracranial DAMGO-induced motor activity. (A) Open-field motor 
activity of adult male wild-type (black; n=15) and congenic Girk1–/– (red; n=15) mice 
during a 60-min period following bilateral intra-VTA infusion of 0 (saline; 
n=15/genotype), 0.01 (n=5-6/genotype), 0.1 (6-7/genotype), 1 (5-8/genotype, and 10 (5-
8/genotype) nmol DAMGO. A main effect of DAMGO dose was observed (F(4,70)=36.2, 
P<0.001), but there was no effect of genotype (F(1,70)=0.005, P=1.0) or  
genotype/concentration interaction (F(4,70)=0.8, P=0.5). (B) Schematic of coronal sections 
(from bregma) depicting cannulae placements in mice used for intra-VTA experiments. 
(C) Open-field motor activity of male wild-type (black; n=11) and congenic Girk1–/– (red; 
n=10) mice during a 60-min test following bilateral intra-RMTg infusion of 0 (saline; 
n=10-11/genotype), 0.01 (n=5-7/genotype), 0.1 (5-7/genotype), 1 (6-10/genotype, and 10 
(6-10/genotype) nmol DAMGO. A main effect of DAMGO dose (F(4,67)=18.2, P<0.001) 
and genotype (F(1,67)=5.2, P<0.05) was observed, but there was no 
genotype/concentration interaction (F(4,67)=2.0, P=0.1). (D) Schematic of cannulae 
placements in mice evaluated in the intra-RMTg DAMGO study. 
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To test whether GIRK channel activation in GABA neurons is sufficient to enhance 
motor activity, we employed a novel direct-acting agonist (ML297) of GIRK1-containing 
GIRK channels [279]. In VTA slices, ML297 induced an outward current in putative 
GABA neurons from wild-type mice, but not in putative GABA neurons from Girk1–/– 
mice (Fig. 2.6A,B). ML297 also evoked no response in VTA DA neurons (Fig. 2.6A), 
suggesting that intracranial infusion of ML297 should selectively inhibit neurons 
expressing GIRK1-containing channels (e.g., VTA GABA neurons) without affecting 
neurons expressing GIRK1-lacking channels (e.g., VTA DA neurons). When 
administered directly to the VTA or RMTg of wild-type mice, ML297 failed to increase 
motor activity (Fig. 2.6C-E). Thus, direct activation of GIRK1-containing channels in the 
VTA and RMTg is insufficient to trigger motor activation. 
 
 
 
 
 
 
 
 
 
 
 
 
53	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Direct activation of GIRK1-containing GIRK channels and motor 
activity. (A) ML297 (10 µM) evoked a Ba2+-sensitive (0.3 mM) outward current in 
putative VTA GABA neurons from wild-type (left, black) but not Girk1–/– (middle, gray) 
mice; scale bars, 15 pA/180 s. ML297 did not evoke an outward current in VTA DA 
neurons (right, black; n=6), as shown in this recording from an eGFP-positive neuron 
from a Pitx3-eGFP mouse; scale bars, 30 pA/200 s. (B) Summary of ML297-induced 
currents in putative VTA GABA neurons from wild-type (n=6) and Girk1–/– (n=5) mice 
(t(9)=2.9, P<0.05). (C) Open-field motor activity of male wild-type mice during a 60-min 
test following bilateral infusion of vehicle (0.1% DMSO, white) or ML297 (10 nmol, 
black) into the VTA (n=10/group; t(18)=0.4, P=0.7) or RMTg (n=9/group; t(16)=0.3, 
P=0.7). (D,E) Schematic of coronal sections (from bregma) depicting cannulae 
placements in mice used for the intra-VTA and intra-RMTg ML297 studies. 
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Morphine-induced activity in mice lacking GIRK channels in DA neurons 
Collectively, the data presented above argue that GIRK channel activation in GABA 
neurons is not required for opioid-induced motor activation. To test whether loss of 
GIRK channels in DA neurons modulates opioid-induced motor activity, Girk2flox/flox 
mice were crossed with B6.SJL-Slc6a3tm1.1c\(cre)Bkmn/J (DAT-Cre) mice, which express 
Cre recombinase under the control of the DA transporter (DAT) promoter. Cre 
recombinase-driven reporter expression in DAT-Cre mice is restricted to DA neurons 
[280]. Immunohistochemical analysis revealed a striking reduction in GIRK2 
immunoreactivity in the VTA from DAT-Cre(+):Girk2flox/flox mice (Fig. 2.7A). 
To assess the functional impact and cell-type specificity of GIRK channel ablation in 
DAT-Cre(+):Girk2flox/flox mice, we measured baclofen-induced GIRK currents in VTA 
DA neurons. To permit direct electrophysiological characterization of DA and non-DA 
VTA neurons, DAT-Cre:Girk2flox/flox mice were crossed with mice expressing eGFP 
under the control of the promoter for the DA neuron-specific transcription factor, Pitx3 
[273]. As predicted, baclofen-induced currents in small eGFP-negative neurons lacking Ih 
current (putative VTA GABA neurons) were comparable in slices from Pitx3-
eGFP(+)/DAT-Cre(+):Girk2flox/flox and Pitx3-eGFP(+)/DAT-Cre(-):Girk2flox/flox mice (Fig. 
2.7B,C). In contrast, baclofen-induced currents in eGFP-positive (DA) VTA neurons 
were dramatically-reduced in slices from Pitx3-eGFP(+)/DAT-Cre(+):Girk2flox/flox mice as 
compared to controls (Fig. 2.7D,E). Importantly, like constitutive Girk2–/– mice, DAT-
Cre(+):Girk2flox/flox mice were more sensitive to the motor-stimulatory effect of systemic 
morphine than DAT-Cre(-):Girk2flox/flox controls (Fig. 2.7F). 
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Since some VTA DA neurons are directly inhibited by MOR agonists [281-284], we 
evaluated the impact of the DA neuron-specific loss of GIRK2 on DAMGO-induced 
currents in VTA DA neurons. DAMGO (3 µM) evoked naloxone-sensitive outward 
currents in a subset (5/25) of VTA DA neurons from Pitx3-eGFP(+)/DAT-Cre(-
):Girk2flox/flox mice (Fig. 2.7G,H). Though a similar fraction of VTA DA neurons from 
Pitx3-eGFP(+)/DAT-Cre(+):Girk2flox/flox mice exhibited DAMGO-induced outward 
currents, current amplitudes were significantly blunted relative to controls, indicating that 
activation of GIRK2-containing channels contributes to the direct inhibitory effect of 
DAMGO in this subset of VTA DA neurons.  
We also asked whether there were differences in the excitability of VTA DA neurons 
from Pitx3-eGFP(+)/DAT-Cre(+):Girk2flox/flox and Pitx3-eGFP(+)/DAT-Cre(-
):Girk2flox/flox mice. VTA DA neurons from both genotypes exhibited tonic spontaneous 
firing patterns (not shown), with no difference in firing rate (Cre(+): 2.2±0.3 vs. Cre(-): 
2.0±0.2 Hz; n=31-33/group; P=0.6). Similarly, there was no difference in rheobase 
(Cre(+): -12±5.0 vs. Cre(-):-13.9±3.6 pA; n=26-30/group; P=0.8) or holding current 
(Vhold = -60 mV; Cre(+): 10.82±17.9 vs. Cre(-): 44.35±20.6 pA; n=26-27/group; P=0.1) 
between Pitx3-eGFP(+)/DAT-Cre(+):Girk2flox/flox and control mice, respectively. Thus, 
the cell-specific loss of GIRK2 did not significantly alter key measures of excitability in 
VTA DA neurons. 
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Figure 2.7. DA neuron-specific ablation of GIRK channels and systemic morphine-
induced motor activity. (A) GIRK2 immunolabeling in midbrain sections from DAT-
Cre(-):Girk2flox/flox and DAT-Cre(+):Girk2flox/flox mice. Images shown were taken from 
slices -2.98 mm relative to bregma. Abbreviations: VTA, ventral tegmental area; SNR, 
substantia nigra pars reticulata. (B) Representative traces evoked by baclofen (Bac, 200 
µM) in putative VTA GABA (eGFP-negative) neurons from Pitx3-eGFP(+)/DAT-Cre(-
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):Girk2flox/flox (left, black) and Pitx3-eGFP(+)/DAT-Cre(+):Girk2flox/flox (right, gray) mice. 
Scale bars: 40 pA/200 s. (C) Summary of baclofen-induced currents in putative VTA 
GABA (eGFP-negative) neurons from Pitx3-eGFP(+)/DAT-Cre(-):Girk2flox/flox (white; 
n=10) and Pitx3-eGFP(+)/GADCre(+):Girk2flox/flox (gray; n=7) mice (t(15)=0.2, P=0.8). 
(D) Representative currents evoked by baclofen (200 µM) in VTA DA (eGFP-positive) 
neurons from Pitx3-eGFP(+)/DAT-Cre(-):Girk2flox/flox (left, black) and Pitx3-
eGFP(+)/DAT-Cre(+):Girk2flox/flox (right, gray) mice. Scale bars: 60 pA/200 s. (E) 
Summary of baclofen-induced currents in VTA DA (eGFP-positive) neurons from Pitx3-
eGFP(+)/DAT-Cre(-):Girk2flox/flox (white; n=10) and Pitx3-eGFP(+)/DAT-
Cre(+):Girk2flox/flox (gray; n=12) mice (t(20)=5.2, P<0.0001). (F) Open-field motor activity 
of DAT-Cre(-):Girk2flox/flox (white; n=6/dose) and DAT-Cre(+):Girk2flox/flox (gray; 
n=12/dose) mice during a 60-min period following systemic administration of saline (0) 
or morphine (3, 10, 30 mg/kg). Main effects of dose (F(3,48)=85.3, P<0.0001) and 
genotype (F(1,16)=2.9, P=0.1) were observed, along with a dose/genotype interaction 
(F(3,48)=2.9, P<0.05). Symbols: ** P<0.01 vs. DAT-Cre(-):Girk2flox/flox mice. (G) 
Responses of DA neurons from DAT-Cre(-):Girk2flox/flox and DAT-Cre(+):Girk2flox/flox 
mice to a saturating concentration of DAMGO (3 µM). DAMGO-induced currents were 
reversed by naloxone (Nal, 10 µM). Scale bars: 40 pA/200 s. (H) Summary of DAMGO-
induced currents in VTA DA neurons from DAT-Cre(-):Girk2flox/flox (5/25 responders; 
80.1±18.4 pA) and DAT-Cre(+):Girk2flox/flox (4/20 responders; 22.7±3.4 pA) mice. 
Symbols: * P<0.05 vs. DAT-Cre(-):Girk2flox/flox mice. 
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Morphine-induced activity in Girk3–/– mice 
Data from DAT-Cre(+):Girk2flox/flox mice suggested that loss of GIRK channels in 
VTA DA neurons contributes in part to the increased sensitivity of constitutive Girk2–/– 
mice to systemic morphine-induced motor activity, and suggests that enhanced GIRK 
channel activity in these neurons might yield diminished opioid sensitivity. Since prior 
work has shown that the residual GIRK channel in VTA DA neurons from Girk3–/– mice 
(GIRK2 homomer) is more sensitive to GABABR-dependent stimulation than its wild-
type counterpart (GIRK2/GIRK3 heteromer) [188], we next evaluated the impact of 
Girk3 ablation on systemic morphine-induced motor activity. Constitutive Girk3–/– mice 
were significantly less sensitive to morphine-induced motor activity than wild-type 
counterparts (Fig. 2.8A). To determine whether the loss of GIRK3 in the VTA underlies 
the diminished sensitivity of Girk3–/– mice to systemic morphine-induced motor activity, 
we restored GIRK3 expression in the VTA of Girk3–/– mice using a recombinant 
lentivirus. Viral expression of GIRK3 in the VTA of Girk3–/– mice restored normal 
sensitivity to the motor-stimulatory effect of morphine (Fig. 2.8A-C). 
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Figure 2.8. Girk3 ablation and rescue: morphine-induced motor activity. (A) Total 
distance traveled by wild-type (white; n=6) and Girk3–/– (gray; n=6) mice, as well as 
Girk3–/– mice given intra-VTA GIRK3 (red; n=5) or control (black; n=5) lentivirus, 
during a 60-min period following systemic administration of saline (0) or morphine (3, 
10, 30 mg/kg). A main effect of dose (F(3,54)=103.4, P<0.0001) and genotype (F(3,18)=3.2, 
P<0.05) was observed, but there was no dose/genotype interaction (F(9,54)=1.8, P=0.1). 
Symbols: **P<0.01 vs. wild-type, ++P<0.01 vs. Girk3–/–, #P<0.05 vs. Girk3–/– + control. 
(B) Representative image showing lentiviral-driven GIRK3-YFP (YFP expression shown 
in red) expression in the VTA of a Girk3–/– mouse. Abbreviations: SN, substantia nigra; 
PBP, parabrachial pigmented nucleus; IF, interfascicular nucleus; MM, medial 
mammillary nucleus. (C) Schematic of coronal sections (from bregma) depicting viral 
expression in mice included in this study. 
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Discussion 
Opioid-induced motor-activation is an unconditioned behavioral response that 
involves increased DA neurotransmission in the mesolimbic (VTA-NAc) pathway [88, 
260]. GIRK channels have been proposed to mediate the direct inhibitory effects of 
opioids on midbrain GABA neurons that suppress VTA DA neuron output, and thus, we 
predicted that loss of GIRK signaling would suppress opioid-induced motor activity. 
Instead, we found that GIRK channel activation in GABA neurons is not required for 
opioid-induced motor activation in mice, nor is it sufficient to evoke an increase in motor 
activity. GIRK channels in VTA DA neurons are, however, a key determinant of 
sensitivity to the motor-stimulatory effect of opioids. 
The opioid-induced disinhibition of VTA DA neurons was proposed initially to 
involve the direct inhibition of local (VTA) GABA neurons [214]. In support of this 
model, MOR expression within the VTA is most prominent in GABA neurons [285], 
VTA GABA neurons synapse onto VTA DA neurons [267, 286, 287], opioids 
hyperpolarize and/or inhibit the spontaneous activity of VTA GABA neurons [214, 281, 
288, 289], and input to VTA DA neurons from VTA GABA neurons is opioid-sensitive 
[267]. Moreover, inhibition of VTA GABA neurons leads to activation of VTA DA 
neurons [286] . Recent evidence, however, suggests that the disinhibition of VTA DA 
neurons reflects the opioid-induced inhibition of GABAergic input from the RMTg [290, 
291]. Indeed, most midbrain (VTA) DA neurons in rodents and non-human primates are 
innervated and inhibited by RMTg GABA projections [290, 292], and this comparably 
dense input may be better poised to regulate the excitability of VTA DA neurons than the 
more sparse input from VTA GABA neurons [287, 293, 294].  
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Whether the opioid-induced disinhibition of VTA DA neurons is attributable to the 
inhibition of VTA or RMTg GABA neurons, or reflects a broad suppression of GABA 
input to VTA DA neurons from these and other structures, including the NAc and ventral 
pallidum [295, 296], our data argue that the opioid-induced inhibition of GABAergic 
input to VTA DA neurons involves a presynaptic mechanism and/or a non-GIRK 
somatodendritic mechanism(s), at least in the mouse. Consistent with the former 
possibility, MOR labeling in the VTA is found on axon terminals of GABA neurons 
[285], and opioid inhibition of GABAergic neurotransmission in several brain regions, 
including the VTA, is mediated by a reduced probability of presynaptic neurotransmitter 
release [266-268]. Furthermore, pharmacological inactivation of the RMTg blocked the 
ability of intra-VTA morphine to activate VTA DA neurons [293], arguing that the 
disinhibitory effect of intra-VTA opioids on VTA DA neurons is due to inhibition of 
RMTg GABA afferents.  
Non-GIRK postsynaptic mechanisms may also contribute to the opioid-induced 
disinhibition of VTA DA neurons. Notably, the opioid-induced hyperpolarization and 
inhibition of spontaneous activity in VTA and RMTg GABA neurons has been observed 
by multiple groups [266, 288, 294]. Indeed, DAMGO suppressed the spontaneous 
activity of 92% of eGFP-positive (GABA) VTA neurons from GAD67-eGFP mice [288]. 
Using this same mouse line, we show here that most VTA GABA neurons lack an 
evident DAMGO-induced inhibitory current, reminiscent of findings in the rat [297]. 
Similarly, only one-third of the RMTg neurons projecting to the ventral midbrain (VTA 
and susbstantia nigra) were hyperpolarized by MOR agonists [266]. Our finding that 
intra-RMTg DAMGO stimulated motor activity, however, argues that the direct 
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inhibition of RMTg neurons is sufficient to stimulate motor activity. Interestingly, 
morphine was reported to suppress excitatory input to RMTg neurons via a GIRK-
independent postsynaptic mechanism [294]. Thus, MOR may couple preferentially to a 
non-GIRK somatodendritic effector(s) in midbrain GABA neurons. At present, the 
behavioral relevance of the opioid-induced, GIRK-dependent and GIRK-independent 
inhibition of midbrain GABA neurons is unclear.  
Some VTA DA neurons express MOR, and both direct excitatory and inhibitory 
effects of MOR activation on VTA DA neurons have been reported [283]. Consistent 
with previous reports [281-283], we found that ~20% of mouse VTA DA neurons were 
inhibited by DAMGO. Moreover, we show that GIRK channel activation mediates the 
direct inhibitory effect of DAMGO on this subset of VTA DA neurons. Disruption of 
MOR-GIRK signaling in these neurons, however, seems unlikely to explain the enhanced 
morphine-induced motor activity observed in Girk2–/– or DAT-Cre(+):Girk2flox/flox mice. 
Indeed, if MOR-GIRK signaling in these neurons underlies the motor-stimulatory effect 
of systemic or intra-VTA opioids, then the loss of GIRK channels should diminish and 
not enhance the opioid-induced behavior. It is possible, however, that this VTA DA 
neuron subpopulation normally tempers opioid-induced motor stimulation, perhaps akin 
to a negative feedback pathway. In this scenario, diminished MOR-GIRK signaling could 
result in enhanced opioid-induced motor stimulation. 
The output of VTA DA neurons is tempered by “long-loop” (GABABR-dependent) 
and D2 DA autoreceptor (D2R)-mediated negative feedback mechanisms that are engaged 
by in vivo administration of drugs of abuse [298, 299]. The GIRK2/GIRK3 channel 
mediates the inhibitory effect of GABABR and D2R activation on VTA DA neurons [188, 
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239]. The enhanced morphine-induced motor activity seen in DAT-Cre(+):Girk2flox/flox 
mice may reflect, therefore, the loss of these feedback mechanisms. In support of this 
contention, key excitability measures in the absence of drug were comparable in VTA 
DA neurons from DAT-Cre(+):Girk2flox/flox and DAT-Cre(-):Girk2flox/flox mice. 
Furthermore, our observations with Girk3–/– mice and viral reconstitution of GIRK3 in 
the VTA, together with previous work showing that Girk3 ablation correlates with 
enhanced sensitivity of the residual GIRK channel to GPCR-dependent activation [180], 
argues that the sensitivity of the VTA DA neuron GIRK channel to GPCR stimulation is 
a critical determinant of morphine-induced motor activity.  
Acute and repeated psychostimulant exposure suppresses GABAB and D2 DA 
receptor-dependent inhibitory signaling in VTA DA neurons [150]. A single injection of 
cocaine, for example, transiently suppressed GABABR-GIRK signaling in VTA DA 
neurons, by triggering a subcellular redistribution of GIRK channels from the membrane 
to intracellular sites [199]. As decreased GIRK-dependent signaling in VTA DA neurons 
should correlate with enhanced opioid-induced motor activity, our findings suggest a 
plausible explanation for behavioral cross-sensitization observed between opioids and 
psychostimulants [300-305].  
While the vast majority of neurons in the mouse VTA are dopaminergic or 
GABAergic [288], some glutamatergic neurons are present as well [84, 306]. Most 
glutamatergic neurons are found in the medial aspect of the VTA [84], including some 
that co-express VGlut2 and TH [85, 307]. We targeted the lateral aspect of the VTA to 
minimize the potential impact of this small neuron population on our study. While many 
of our experiments utilized transgenic mice with fluorescently-tagged GABA and DA 
64	  
	  
neurons, some experiments relied on a combination of cell size (apparent capacitance) 
and Ih current size to identify putative VTA GABA and DA neurons. This combination of 
features, as well as the amplitude of the baclofen-induced somatodendritic current, has 
proven useful for distinguishing between DA and GABA neurons in the mouse VTA 
[180, 188, 199]. We cannot exclude the possibility, however, that some putative VTA DA 
and GABA neurons evaluated in this study were glutamatergic neurons. At present, the 
expression of GIRK channels and MOR in VTA glutamatergic neurons, and their 
relevance to the motor-stimulatory effects of systemic and intracranial opioids, are 
unclear. 
Opioids such as morphine are the most commonly-administered drugs for pain, despite 
possessing an unfavorable side effect profile and significant addictive liability [204]. 
Given the increase in abuse of prescription opioids [308], it is particularly important that 
we understand the circuitry, cell types, and mechanisms mediating both the beneficial and 
problematic effects of opioids. These insights may suggest novel approaches to eliciting 
the beneficial outcome associated with opioids (analgesia) while avoiding undesirable 
side effects (addiction). Data described herein suggest that the unique GIRK channel 
subtype (GIRK2/GIRK3 heteromer) in VTA DA neurons sets the sensitivity of the 
mesolimbic circuit to morphine. Given that previous work has implicated this channel in 
circuit-level and behavioral effects of other drugs of abuse [188, 309], these findings 
suggest that therapeutic approaches targeting the GIRK2/GIRK3 channel might prove 
useful for treating some aspects of drug addiction. 
 
 
 
 
65	  
	  
Author Contributions for Chapter 3: 
 
 
McCall NM: Responsible for electrophysiology data presented in Chapter 3- Figure 3.1 
C/D. Contributions included development of study conception and design, 
acquisition of data, analysis and interpretation of data, drafting of 
manuscript, and critical revision. 
 
Kotecki L: Responsible for IHC (Figure 3.1B) and behavioral data presented in Chapter 
3-Figure 3.2, 3.3, 3.4. Contributions included development of study 
conception and design, acquisition of data, analysis and interpretation of 
data, drafting of manuscript, and critical revision. 
 
Carlblom N: Assisted with the collection of behavioral data of DATCre:Girk2flox/flox mice 
locomotor response to acute and repeated cocaine in Figure 3.2 and 3.3. 
 
Wickman K: Contributions included development of study conception and design, 
interpretation of data, and drafting of manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
66	  
	  
 
 
 
 
 
CHAPTER 3 
 
Loss of GIRK channels in dopamine neurons blunts D2R 
autoinhibitory feedback and enhances reward-related 
behavioral response to cocaine 
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Introduction 
The use of illicit substances, such as cocaine, continues to be a global problem, with 
the World Health Organization estimating that in 2008, 155 to 250 million people (~4.5% 
of the world’s population age 15-64) used illicit substances [4].  Drug addiction is a 
chronic relapsing disorder defined by compulsive drug seeking and taking despite the 
presence of negative consequences [1, 310].  Many of the current pharmacotherapies for 
addiction are targeted toward the receptor of interest, but are not very effective in treating 
addiction and often have undesirable off target effects [135].  To more effectively treat 
and potentially prevent addiction, a fundamental understanding of the underlying cellular 
mechanisms of addiction is needed.  The mesocorticolimbic dopamine (DA) system, 
which consists of the ventral tegmental area (VTA) and its reciprocal connections with 
downstream targets such as the nucleus accumbens (NAc) and prefrontal cortex (PFC), is 
a critical cellular substrate for addiction.  Indeed, both acute and repeated cocaine 
exposure can alter excitatory and inhibitory signaling within the mesocorticolimbic DA 
system [150].  Cocaine enhances the presence of DA in synapses through the blockade of 
the DA transporter (DAT) [256, 310].  This increase in extracellular DA levels in the 
mesocorticolimbic pathway is a critical component of drug-induced reward-related 
behaviors, such as exploration (motor activity) and drug seeking/wanting [252, 256].  
While much of the research on the underlying cellular mechanisms of cocaine addiction 
has focused on drug-induced adaptations in excitatory neurotransmission in the 
mesocorticolimbic DA system [122, 131, 310, 311], recent work has shown that cocaine 
exposure also triggers modifications to inhibitory signaling [91, 123, 298, 299, 312-317].   
68	  
	  
In addition to increasing DA levels in downstream targets, cocaine increases 
extracellular levels of DA in the VTA, where DA transporters are also present. This 
extracellular DA in the VTA binds to somatodendritic inhibitory Gi/o G-protein coupled 
DA receptors (Type 2 DA receptors; D2R) [233].  D2R receptor activation results in 
neuronal inhibition through the activation of G protein gated inwardly rectifying K+ 
(GIRK/Kir3) channels, which serves as a key autoinhibitory mechanism designed to 
temper VTA-mediated DA neurotransmission [150, 298, 299, 318, 319].  GIRK channels 
have been shown to mediate the postsynaptic inhibitory effects of many neurotransmitters 
within the CNS, including DA and GABA [164, 165, 239].  VTA DA neurons express 
GIRK2/GIRK3 heteromeric channels [180, 188], and DA neurons of the VTA appear to 
be the only cell type that exclusively expresses this unique GIRK channel.  
 The importance of GIRK channel activity to DA-dependent reward-related behaviors 
is indicated by the observation that constitutive Girk-/- mice exhibit altered baseline and 
drug-induced reward-related behaviors.  Constitutive Girk2-/- mice exhibit baseline 
hyperactivity in their home cage and open field test [276, 320], phenotypes that can be 
normalized by systemic administration of SCH 23390, a D1R antagonist [320].   
Constitutive Girk2-/- mice also show enhanced motor activation following both systemic 
morphine and cocaine administration; however, Girk3-/- mice exhibit attenuated motor 
activation to these drugs [228, 321].  Constitutive Girk2-/- and Girk3-/- mice also exhibit 
decreased cocaine self-administration [322].  These results, along with prior work 
showing that the GIRK channel in VTA DA neurons of Girk3-/- mice (GIRK2 homomer) 
is more sensitive to GABABR-dependent stimulation than its wild-type counterpart 
(GIRK2/GIRK3 heteromer) [188], suggest that the loss of GIRK2 in VTA DA neurons 
69	  
	  
increases the sensitivity of these animals to the cellular and behavioral effects of drugs of 
abuse. In the present study, we utilized a DA neuron-specific Girk2-/- mouse line 
(DATCre:Girk2flox/flox) [321], to probe the relevance of GIRK channels in VTA DA 
neurons on D2R autoinhibitory signaling and cocaine-induced reward-related behavior.  
Using these novel mutant mice and pharmacological tools, we found that the loss of 
GIRK channels in DA neurons blunts D2R autoinhibitory feedback and enhances the 
motor and reward-related behavioral responses of these mice to cocaine.   
 
Materials and Methods 
Animals.   
Animal use was approved by the Institutional Animal Care and Use Committee at the 
University of Minnesota. The generation of Girk2flox/flox mice in partnership with 
InGenious Laboratory was previously described in Chapter 2 [321].  Pitx3-eGFP mice 
were provided by Dr. Meng Li.  B6.SJL-slc6a3tm1.1c\(cre)Bkmn/J (DATCre; #006660) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were maintained 
on a 12 h light/dark cycle, with food and water available ad libitum. 
Drugs.  
Cocaine hydrochloride, sulpiride, quinpirole, and tetrodotoxin (TTX) were purchased 
from Sigma (St. Louis, MO).  
Motor activity.  
 Systemic cocaine-induced locomotor activity assessments in DATCre(+/-
):Girk2flox/flox mice were performed in automated open-field activity chambers (Med-
Associates Inc.; St Albans, VT), as described [276]. In brief, male and female subjects (7-
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10 wk) were handled and acclimated to the testing room for 1 h prior to test day, followed 
by habituation to activity chambers and systemic injections (saline i.p.) over 2 daily 
sessions. Total distance traveled during the 60-min period following the second day of 
saline injection was defined as the response to 0 mg/kg cocaine. For acute cocaine-
induced activity studies, subjects were given 1 of 3 cocaine doses (3, 15, 30 mg/kg i.p.). 
For repeated cocaine-induced activity (sensitization) studies, subjects received 15 mg/kg 
cocaine for 5 consecutive days, and a 15 mg/kg cocaine challenge administered 10-12 
days after the last injection. Cocaine sensitization occurred if the activity response was 
higher on cocaine day 5 (C5) than cocaine day 1 (C1) or challenge (ES) > C1. 
 Conditioned Place Preference (CPP).  
 The CPP test was conducted in an apparatus divided into two compartments with a 
guillotine-style door as previously described (Med Associates Inc.; St Albans, VT) [323]. 
The floor of one compartment consisted of an array of stainless steel rods (grid) and the 
other compartment consisted of thin chicken wire (mesh). During the preconditioning 
test, mice were placed in the apparatus and allowed free exploration for 15 min; time 
spent in the “grid” and “mesh” chambers was recorded. Mice were then assigned to drug 
treatment (15 mg/kg cocaine) or vehicle (saline) treatment groups and paired with the 
least preferred compartment (CS+). The other chamber (CS-) was paired with a saline 
treatment. During the AM conditioning trials, subjects were injected with saline and 
confined (30 min) to the corresponding CS- chamber.  During the PM conditioning trials, 
subjects were injected with saline or cocaine and confined (30 min) to the corresponding 
CS+ chamber. A total of 3 training sessions was performed. Side preferences were 
evaluated after the last day of training and place preference was determined by 
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calculating the difference in time spent in the CS+ and CS- chambers during the test 
sessions; “preference” is defined as (CS+ − CS-) within a test session. 
Slice Electrophysiology.  
 Horizontal slices (225 µm) from male and female Pitx3-eGFP(+)/DATCre(+/-
):Girk2flox/flox mice (5-6 wk) were prepared as previously described in Chapter 2 [321].  
Studies involved targeted evaluation of VTA DA neurons, as defined by eGFP expression 
in VTA neurons from Pitx3-eGFP [272]. Upon achieving whole-cell access, Ih was 
measured in voltage-clamp mode using a 1-s voltage ramp (-60 to -120 mV).  
Subsequently, spontaneous activity was measured in current-clamp mode (I=0) for 1 min. 
Following a 3 to 5-min stabilization period (Vhold = - 60 mV), changes in holding current 
evoked by quinpirole were measured, as described [199]. Other cell parameters, including 
series resistance, capacitance, and input resistance, were tracked throughout the 
experiment. All command potentials factored in junction potential of -15 mV, predicted 
using JPCalc software (Molecular Devices). 
Immunohistochemistry.  
Pitx3-eGFP mice (7-10 wk) were given a euthanizing dose of ketamine/xylazine 
(250 and 25 mg/kg i.p., respectively) and perfused transcardially with Ca2+-free Tyrode’s 
solution followed by 4% paraformaldehyde containing 14% picric acid. Brains were post-
fixed overnight in Sorenson’s Buffer containing 10% sucrose at 4˚C. Tissue was 
sectioned coronally at 12 µm by cryostat and mounted to slides. Staining was performed 
as described [321].  Sections were exposed to sheep anti-Tyrosine Hydroxylase antibody 
(1:1000; Alomone labs) and donkey anti-sheep IgG Cy3 secondary antibody (1:500; 
Jackson Immunoresearch Laboratories, Inc.; West Grove, PA)  
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Data analysis.  
Data are presented throughout as the mean ± SEM. Statistical analyses were 
performed using Prism 6 (GraphPad Software, Inc.; La Jolla, CA) and SigmaPlot 11.0 
(Systat Software, Inc.; San Jose, CA).  Electrophysiological and behavioral data were 
analyzed with a Student’s t test, one-way ANOVA, or two-way repeated measures 
ANOVA followed by individual comparisons using the Bonferroni post-test method, as 
appropriate.  Where no sex differences were observed, data were pooled to increase 
statistical power.  For all statistical comparisons, differences were considered significant 
if P<0.05. 
 
Results 
D2R-dependent signaling is reduced in VTA DA neurons from DATCre(+):Girk2flox/flox 
mice 
Previous work suggests that the GABABR- and D2R-dependent inhibition of midbrain 
DA neurons is mediated in large part by activation of GIRK channels containing GIRK2 
[188, 239]. Described in detail in Chapter 2, we reported the creation of a DA neuron-
specific conditional Girk2 knockout mouse line, DAT-Cre:Girk2flox/flox (Fig 3.1A).  We 
demonstrated that DAT-Cre(+):Girk2flox/flox mice showed a striking reduction in GIRK2 
immunoreactivity in the VTA and significantly attenuated GABABR-dependent GIRK 
currents [321]. To evaluate the impact of the DA neuron-specific loss of Girk2 on D2R-
dependent inhibition, we measured somatodendritic currents evoked by the D2R agonist 
quinpirole in VTA DA neurons in DATCre(+/-):Girk2flox/flox mice. To permit direct 
electrophysiological characterization of DA and non-DA VTA neurons, DAT-
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Cre:Girk2flox/flox mice were crossed with mice expressing eGFP under the control of the 
promoter for Pitx3, which is a DA neuron-specific transcription factor [273].  eGFP 
labeling in this line correlates well with DA neuron markers [180], including tyrosine 
hydroxylase (TH, Fig. 3.1B). VTA DA neurons from Pitx3-eGFP(+)/DAT-Cre(-
):Girk2flox/flox mice displayed outward currents in response to bath application of 
quinpirole that was reversed by the D2R  antagonist sulpiride. As predicted, quinpirole-
induced current amplitudes in eGFP-positive (DA) VTA neurons were dramatically-
reduced in slices from Pitx3-eGFP(+)/DAT-Cre(+):Girk2flox/flox mice as compared to 
Pitx3-eGFP(+)/DAT-Cre(-):Girk2flox/flox controls (Fig. 3.1C,D). We did not observe any 
sex difference in quinpirole-induced current amplitude (data not shown).  We also 
observed no significant effect of sex or genotype on other properties of VTA DA neurons 
(Table 3.1). 
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Figure 3.1. DA neuron-specific ablation of GIRK channels reduces D2R-dependent 
signaling. (A) Schematic depicting how DA neuron-specific Girk2 KO mouse line 
(DATCre(+/-):Girk2flox/flox) was generated. (B) Immunohistochemistry showing Pitx3-
eGPF labeling and tyrosine hydroxylase (TH) overlap in VTA DA neurons in sections 
taken from a Pitx3-eGPF (+) mouse. (C) Representative currents (Vhold = -60 mV) 
evoked by quinpirole (20 µM) in VTA DA neurons from DATCre(+):Girk2flox/flox (red) 
and DATCre(-):Girk2flox/flox (black) control mice.  Currents were reversed by the D2R 
antagonist sulpiride (5 µM). (D) Summary of peak quinpirole-induced currents in VTA 
DA neurons from DATCre(+):Girk2flox/flox (red) and DATCre(-):Girk2flox/flox (black) 
control mice. Symbols (*** P<0.001) (n=19-23 recordings/genotype).  
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Parameter DATCre(-):Girk2flox/flox DATCre(+):Girk2flox/flox 
N (n) 23 (11) 19 (10) 
Mouse age (d) 40 40 
CM (pF) 49 ± 4 44 ± 3 
RMP (mV) -38 ± 1 -38 ± 2 
Ih amplitude (pA) -165 ± 49 -68 ± 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Electrophysiological properties of VTA DA neurons from DATCre(+/-
):Girk2flox/flox mice (related to Figure 1). Summary of intrinsic and active 
electrophysiological properties of VTA DA neurons from Pitx3-eGFP(+)/DAT-Cre(-
):Girk2flox/flox and Pitx3-eGFP(+)/DAT-Cre(+):Girk2flox/flox mice. N (n), number of 
recordings and number of animals; mouse age (d); CM, apparent membrane capacitance; 
RMP, resting membrane potential; Ih, hyperpolarization-activated cation current. No 
differences were found in CM, RMP, or Ih, between Pitx3-eGFP(+)/DAT-Cre(-
):Girk2flox/flox and Pitx3-eGFP(+)/DAT-Cre(+):Girk2flox/flox mice.  
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GIRK signaling in VTA DA neurons and cocaine-induced behavior  
 Exposure to acute cocaine produces an unconditioned response of motor stimulation.  
Repeated exposure to cocaine results in behavioral sensitization, which is characterized 
by an enhanced response to subsequent cocaine exposure.  Cocaine behavioral 
sensitization has been likened to drug craving and is thought to be a key component of 
drug relapse [150, 324, 325].  We have previously reported that constitutive Girk2-/- mice 
exhibited increased sensitivity to the motor-stimulatory effects of acute and repeated 
systemic cocaine [228, 322].  To test whether this enhanced sensitivity to cocaine in 
Girk2-/- mice was attributable to a loss of GIRK-dependent signaling in VTA DA 
neurons, we evaluated the impact of DA neuron-specific GIRK ablation on acute and 
repeated systemic cocaine-induced motor activity.   
 DATCre(+/-):Girk2flox/flox mice were acclimated for 3 days (d) to handling and the 
injection protocol prior to acute cocaine exposure (Fig 3.2A).  While Girk2-/- mice had 
elevated levels of baseline motor activity [228], DATCre(+):Girk2flox/flox mice exhibited 
slightly elevated baseline motor activity (saline day 2, S2), but this difference was not 
statistically significant.  Since global ablation of Girk2 correlated with increased 
sensitivity to cocaine in this task, we predicted that DATCre(+):Girk2flox/flox mice would 
exhibit enhanced acute systemic cocaine-induced motor activity.  Both DATCre(-
):Girk2flox/flox and DATCre(+):Girk2flox/flox mice exhibited a robust dose-dependent 
increase in motor activity following acute systemic cocaine injection (Fig 3.2B).  As 
predicted, DATCre(+):Girk2flox/flox mice exhibited enhanced motor activity response at all 
cocaine doses, with significant genotype differences observed at the two higher doses of 
cocaine  (15 and 30 mg/kg), similar to cocaine responses in constitutive Girk2-/- mice. 
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Figure 3.2. DA neuron-specific ablation of GIRK channels enhances acute cocaine-
induced motor stimulation. (A) The acute cocaine treatment study included three 
acclimation days (H, S1, S2) followed by single cocaine injection (3, 15, 30 mg/kg i.p.). 
(B) Distance traveled (m) following saline (0) injection on the 2nd saline day (S2), and 
after cocaine injection (n=11-19 per treatment/genotype). The DATCre(+):Girk2flox/flox 
mice showed enhanced locomotor responses to 15 and 30 mg/kg cocaine compared to 
DATCre(-):Girk2flox/flox controls. Symbols (*** P<0.001). 
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 To measure cocaine behavioral sensitization, mice were acclimated to the handling 
and injection protocol for 3d prior to 5d of repeated 15 mg/kg cocaine exposure (Fig 
3.3A).  DATCre(+):Girk2flox/flox mice exhibited an enhanced motor activity response to 
repeated cocaine administration, as compared to controls (Fig 3.3B).  
DATCre(+):Girk2flox/flox mice showed elevated cocaine-induced activity levels on every 
day of cocaine exposure (C1-C5). Both DATCre(-):Girk2flox/flox and 
DATCre(+):Girk2flox/flox mice displayed sensitization to the repeated cocaine dosing 
paradigm.   However, DATCre(+):Girk2flox/flox mice showed a reduced magnitude of 
sensitization (ratio C5:C1 and ES:C1) compared to DATCre(-):Girk2flox/flox controls, 
suggesting that DATCre(+):Girk2flox/flox mice show some level of pre-sensitization to the  
behavioral effects of cocaine (Fig 3.3C). These results argue that the loss of GIRK-
dependent signaling in VTA DA neurons alters the sensitivity to cocaine-induced 
locomotor activity. 
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Figure 3.3. DA neuron-specific ablation of GIRK channels alters cocaine 
sensitization. (A) Schematic of repeated cocaine testing protocol. (B) Distance traveled 
(m) following saline (S2) injection, and after the 1st (C1), 5th (C5), and challenge 
injection of cocaine (ES) (n=17-19 per treatment/genotype). The DATCre(+):Girk2flox/flox 
mice showed enhanced locomotor responses compared to DATCre(-):Girk2flox/flox 
controls throughout the test. (C) Both groups showed sensitization: C5 response>C1 
response and ES challenge response>C1 response.  DATCre(+):Girk2flox/flox mice showed 
a reduced magnitude of sensitization (ratio C5:C1 and ES:C1) to DATCre(-):Girk2flox/flox 
mice, suggesting a pre-sensitized state.  Symbols (* P<0.05, ** P<0.01, *** P<0.001). 
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We next assessed the effect that the loss of GIRK-dependent signaling in VTA DA 
neurons had on the rewarding effect of cocaine.  We used a 3d-conditioning session 
conditioned place preference test for 15 mg/kg cocaine [323], a dose that showed 
genotype differences in locomotor sensitivity to both acute and repeated cocaine 
exposure (Fig 3.4A).  Both DATCre(-):Girk2flox/flox and DATCre(+):Girk2flox/flox mice 
established a conditioned place preference for cocaine using this protocol, however there 
was no difference between genotypes with respect to preference magnitude (Fig 3.4B).  
While these results do not support the contention that GIRK-dependent signaling in VTA 
DA neurons is important to the rewarding effect of cocaine, it is possible that 15 mg/kg is 
a saturating dose of cocaine.   Repeated studies with a lower dose of cocaine may yield a 
genotype difference, as was the case in similar cocaine CPP studies done with DA 
neuron-specific autoreceptor D2R-/- (AutoDrd2KO) mice [235].   
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Figure 3.4. DA neuron-specific ablation of GIRK channels does not impact cocaine 
reward. (A) Schematic of CPP testing protocol. (B) Difference in time spent by 
DATCre(-):Girk2flox/flox and DATCre(+):Girk2flox/flox mice between the drug-paired (CS+) 
and saline-paired (CS-) sides of a CPP chamber (preference (CS+-CS-)), measured after 
three conditioning days with cocaine (15mg/kg i.p.). Both cocaine-paired groups showed 
a significant preference to saline, but there was no difference between genotype. Symbols 
(^^p<0.01) n=10-14 mice per treatment/genotype.  
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Discussion 
 Cocaine exposure triggers an increase in extracellular DA levels within the VTA and 
in downstream targets of the VTA, such as the NAc [256, 310].  The increase in 
extracellular DA within the VTA triggers a key autoinhibitory mechanism designed to 
reduce VTA DA neurotransmission [298, 318, 319].  The extracellular DA binds to D2R 
autoreceptors, which triggers the activation of Gi/o G proteins and subsequently GIRK 
channels [150].  GIRK channel activation results in cellular hyperpolarization and 
suppresses VTA DA neuron activity [164, 165].  Dysregulation of this autoinhibitory 
mechanism of VTA DA neurons may contribute to the addictive properties of drugs of 
abuse [150, 233, 236, 326].  
The present studies sought to evaluate the role of autoinhibitory feedback on 
inhibitory signaling in VTA DA neurons and its relevance to addiction-related behaviors 
linked to acute and repeated cocaine exposure.  We found that VTA DA neurons in 
DATCre(+):Girk2flox/flox mice do not show any difference in excitability at baseline 
(RMP, spontaneous activity, and rheobase), but they do show a significant reduction in 
inhibitory D2R-GIRK signaling [321], suggesting that the DATCre(+):Girk2flox/flox line 
represents a loss-of-function model for the autoinhibitory feedback of VTA DA neurons.  
Interestingly, mice lacking inhibitory feedback to VTA DA neurons, exhibited enhanced 
cocaine-induced motor stimulation following both acute and repeated cocaine exposure.  
What is missing from these studies is confirmation that DATCre(+):Girk2flox/flox mice do, 
in fact, show enhanced DA neurotransmission.  Fast-scan cyclic voltammetry (FSCV) 
can be used to measure DA levels in the VTA and downstream targets, including the 
NAc.  Previous studies with mice lacking autoinhibitory D2R in DA neurons revealed 
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increased DA release in the striatum compared to wild-type controls [235, 236].  Based 
on these findings, and our initial results characterizing D2R-GIRK signaling in VTA DA 
neurons of our conditional knockout line, we would expect to see elevated extracellular 
DA levels following VTA stimulation in DATCre(+):Girk2flox/flox mice .  
The loss of Girk2 in DA neurons alters the locomotor response to cocaine, with 
DATCre(+):Girk2flox/flox mice showing “pre-sensitization”, or an enhanced initial response 
to cocaine.  However, to further examine the influence of GIRK-dependent signaling on 
cocaine reward, we need to test this mouse model using established reward behavioral 
paradigms, such as CPP or self-administration.  Our initial CPP results show that cocaine 
was effective at establishing a CPP in both DATCre(+):Girk2flox/flox and DATCre(-
):Girk2flox/flox mice, but there was no difference in the magnitude of CPP as we predicted.  
Previous studies characterizing cocaine CPP in C57BL/6J mice have concluded, 
however, that there is no dose-response relationship to CPP magnitude for cocaine in the 
4-12 mg/kg range.  Nevertheless, a significant effect of the number of cocaine-pairing 
sessions on CPP magnitude can be observed; indeed, CPP magnitude following four 
cocaine training sessions is greater than that observed following 1 or 2 sessions [327-
330].  In order to better test the influence of GIRK-dependent signaling on cocaine 
reward, we have designed a low dose cocaine CPP protocol to assess the impact of the 
number of training sessions on CPP magnitude. This protocol consists of two pretest 
preference days, 4 days of training (2 saline/2 cocaine) followed by a test day, and 
another 4 days of training (2 saline/ 2 cocaine) followed by test day.  If the loss of Girk2 
in DA neurons enhances the sensitivity of the subject to cocaine, we would expect 
DATCre(+):Girk2flox/flox mice to show enhanced CPP magnitude between 4 cocaine 
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training sessions than that observed following 2 sessions, or a difference in CPP 
preference between genotypes on the first test day after only 2 drug paired sessions.   
The GIRK channel found in VTA DA neurons, GIRK2/GIRK3 heteromer, is unique 
and may be a key mediator of behavioral sensitivity to drugs of abuse [180, 188].  
Previous studies involving the global loss of Girk2 have established its importance in the 
motor-stimulatory effects of drugs of abuse, such as systemic morphine and cocaine [228, 
321].  The results of this study confirm that DA neuron specific loss of Girk2 results in a 
similar enhanced motor-stimulatory profile to drugs of abuse.  Interestingly, constitutive 
Girk3-/- exhibit decreased sensitivity to the motor-stimulatory effect of morphine, ethanol, 
and cocaine [228, 321, 331, 332], which can be restored by viral re-repression of Girk3 in 
the VTA.  These results, and work done by Dr. Christian Lüscher’s lab, suggest that 
GIRK channel subunit composition in VTA DA neurons can influence the sensitivity to 
drugs of abuse.   Thus, the loss of Girk2 (i.e. no functional GIRK channels) removes all 
GPCR-GIRK inhibitory control, while the loss of Girk3 (i.e. GIRK2 homomeric 
channels) results in enhanced sensitivity to GPCR-dependent activation.  Collectively, 
these findings support the emerging hypothesis that the unique GIRK channel found in 
VTA DA neurons, the GIRK2/GIRK3 channel, mediates the behavioral sensitivity to 
various drugs of abuse, and might prove to be a useful target for treating some aspects of 
drug addiction. 
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General Summary  
Although drugs of abuse exert their effects through a variety of molecular and 
cellular targets, they also produce overlapping behavioral effects, suggesting a common 
neuronal target that is critical to addiction-related behaviors [197, 198].  GIRK channel 
activity has been shown to be a key regulator of excitability in the CNS.  Disruption or 
dysregulation of GIRK-dependent signaling is associated with many disorders, including 
Down syndrome, Parkinson’s disease, psychiatric disorders (depression, anxiety, ADHD, 
epilepsy, schizophrenia), and drug addiction [165, 186, 187, 190-193].  GIRK-dependent 
signaling has also been shown to play a role in alterations to cellular activity and 
behavior following exposure to various drugs of abuse [188, 195, 199, 200].   Current 
pharmacotherapies for addiction are targeted toward relevant GPCRs, but are not very 
effective in treating addiction and often have undesirable off target effects [135].  More 
direct targeting of GIRK channels may provide more effective treatment of addiction and 
other CNS disorders.   
Using electrophysiological, genetic, and pharmacologic approaches, we have 
shown the nuances of subunit composition, expression, function, and drug-induced 
adaptations of GPCR-GIRK signaling in the mesocorticolimbic DA system.  We 
demonstrated in Chapter 2 that GIRK-dependent signaling in VTA DA neurons, but not 
midbrain GABA neurons, is required for opioid-induced motor-stimulation.  Further, the 
GIRK2/GIRK3 heteromer found in VTA DA neurons regulates sensitivity to the motor-
stimulatory effect of opioids [321]. In addition to its importance to opioid reward, the 
GIRK2/GIRK3 heteromer found in VTA DA neurons may also play an important role in 
regulating cocaine sensitivity.  This is supported by work described in Chapter 3 showing 
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the loss of GIRK-dependent signaling in VTA DA neurons blunts D2R autoinhibitory 
feedback and enhances reward-related behavioral responses to cocaine.  Thus, the unique 
GIRK channel expressed in VTA DA neurons, GIRK2/GIRK3 heteromer, may be a 
therapeutic target to regulate the sensitivity of the mesocorticolimbic DA system to 
various drugs of abuse. 
The relevance of GIRK channels to the cellular and reward-related behavioral 
effects of opioids 
The mesocorticolimbic DA system, comprised of the VTA and reciprocal 
connections to downstream targets, mediates the reward-related behavioral effects of 
drugs of abuse, including opioids [74]. Since the 1980s, it was believed that GIRK 
channels were responsible for mediating the direct inhibitory effect of opioids on VTA 
GABA neurons, thus disinhibiting the VTA DA neurons, resulting in enhanced DA 
neurotransmission [83, 214].  The direct inhibitory effect of opioids was thought to be 
mediated by the MOR activation of GIRK channels.  
Accordingly, we predicted that a loss of GIRK signaling in VTA GABA neurons 
would reduce the opioid-induced disinhibition of VTA DA neurons, resulting in reduced 
motor-stimulation.  We found that VTA GABA neurons do indeed express GIRK 
channels comprised of GIRK1 and GIRK2 subunits; however, genetic ablation of either 
GIRK subunit failed to reduce the motor-stimulatory effect of opioids.  Additionally, 
direct stimulation of GIRK1-containing channels on VTA GABA neurons with the novel 
small molecule activator, ML297, was not sufficient to induce locomotor activation.   
Surprisingly, our results indicate that manipulations to GIRK-dependent signaling in 
VTA DA neurons were capable of altering opioid-induced motor-stimulation.  These 
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genetic manipulations to enhance or suppress GIRK channel function correlated with 
decreased and increased sensitivity to opioid-induced motor-stimulation. Collectively, 
this work suggests that the unique GIRK channel found in VTA DA neurons, a 
GIRK2/GIRK3 heteromer, regulates the behavioral sensitivity to opioids. 
While many cellular and behavioral effects of opioids have been linked to GIRK-
dependent signaling, opioids can also exert their effects through presynaptic and non-
GIRK somatodendritic mechanisms.  The site(s) of action of MOR agonists that are most 
relevant to opioid reward-related signaling and behavior remain unclear.  MOR signaling 
results in the activation of a number of downstream targets including the inhibition of 
adenylyl cyclase, the activation of other K+ channels, and the inhibition of voltage-gated 
Ca2+ channels.  MORs are found at neuron terminals (presynaptic) and somatodendritic 
sites in VTA GABA neurons [208]. MORs found at presynaptic sites are commonly-
associated with the inhibition of voltage-gated Ca2+ channels, leading to reduced Ca2+ 
entry and neurotransmitter release [333]. MORs found at somatodendritic locations are 
commonly-associated with K+ channel activation [208].  Although our studies argue 
against the involvement of GIRK channels, there may be other K+ channels present that 
can be activated by opioids, such as TREK channels [334]. One explanation for our 
results showing the lack of GIRK involvement in VTA GABA neurons to opioid-induced 
motor stimulation is that MOR may couple preferentially to a non-GIRK effector in VTA 
GABA neurons.  The relevant contributions of non-GIRK mechanisms can be assessed 
using genetic and pharmacologic approaches to modulate different K+ and/or voltage-
gated Ca2+ channel activity, and/or measure the opioid-induced disinhibition of VTA DA 
neurons, as well as opioid-induced changes in firing rate (Hz).  At this point, it is still 
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unclear through which mechanism opioids work to exert their direct inhibitory effects on 
midbrain GABA neurons, and how this results in disinhibition of VTA DA neurons. 
The understanding of neuron subtypes within the VTA has significantly evolved 
since our initial investigations into opioid signaling in the VTA.  Recent studies have 
found that VTA DA neurons are actually a heterogeneous population of DA neurons that 
vary in projection targets and electrophysiological properties.  VTA DA neurons exhibit 
distinct functional properties that can be directly linked to their projection target [297, 
335, 336].  As a result, a random evaluation of VTA DA neurons might give variable 
results and make outcomes difficult to interpret.  An example of VTA DA diversity can 
be seen in Figure 2. 4D/E, which showed that only 1/3 of the VTA DA neurons sampled, 
showed a direct inhibitory response to DAMGO. Given the relevance of DA 
neurotransmission in the NAc and mPFC to the acute rewarding effect of opioids, a 
retrograde labeling approach could be used to label specific VTA DA neuron 
subpopulations based on their projection sites, as was previously done for neurons from 
the mPFC [187].  These experiments would be done in Pitx3-eGFP(+) mice to allow for 
easy identification of eGFP(+) cells (i.e. DA neurons) that also express fluorescent 
retrobeads.  eGFP(+)/retrobead(+) neurons would be targeted for electrophysiological 
evaluation to probe the impact of projection targets on direct MOR actions on VTA DA 
neurons.  
While evidence has shown that GIRK-dependent signaling mediates the spinal 
analgesic effects of opioids and sensitivity to the motor-stimulatory effect of opioids 
[270, 271, 321, 337], it is unclear if alterations to GIRK channels activity would alter 
opioid reward.  For the studies discussed in Chapter 2, we focused on opioid-induced 
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motor activation because it is an unconditioned behavioral response to opioids that is 
dependent on VTA-NAc DA neurotransmission [212, 260].  However, to directly connect 
GIRK-dependent signaling in VTA DA neurons to opioid reward, we would need to use 
alternative behavioral paradigms, such as CPP and/or self-administration (SA).  We 
would begin by looking at morphine CPP in our GADCre:Girk2flox/flox and 
DATCre:Girk2flox/flox mice.  Given that the loss of Girk2 in GABA neurons had no 
apparent effect on morphine-induced motor stimulation, we would not expect to see any 
effect on CPP responses to morphine in GADCre(+/-):Girk2flox/flox mice.  However, we 
would expect that the DATCre(+):Girk2flox/flox mice would exhibit altered CPP to 
morphine compared to DATCre(-):Girk2flox/flox controls.   
In addition to the improvements made in our understanding of VTA DA neuron 
heterogeneity, recent studies have highlighted the importance of another GABAergic 
structure to the activity of VTA DA neurons, the rostromedial tegmental nucleus 
(RMTg).  While it has been shown that RMTg GABA neurons can regulate the activity of 
VTA DA neurons and are sensitive to opioids [266, 267, 287, 288, 290-294], our initial 
studies suggest that opioid-induced suppression of GIRK-dependent signaling in the 
RMTg is not responsible for the disinhibition of VTA DA neurons.  However, there is 
still much to be learned regarding the GIRK subunit composition and the importance of 
MOR-GIRK signaling to the activity of RMTg GABA neurons.  We chose to use Girk1-/- 
mice for our RMTg studies based on the evidence that the predominant GIRK channel 
within the CNS is the GIRK1/GIRK2 heteromer.  Although this was a logical first step, 
RMTg GABA neurons may not express GIRK1 and instead express a more unique GIRK 
channel subtype, as is the case for VTA DA neurons.  The lack of GIRK1-containing 
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channels could explain why we did not see a difference in DAMGO-induced locomotor 
activity between Girk1-/- and WT mice. Direct activation of GIRK1-containing channels 
with ML297 in the RMTg also failed to stimulate motor activity.  More experiments are 
needed to examine the GIRK subunit composition of RMTg GABA neurons.  This could 
be accomplished using single cell RT-PCR, similar to the approach used for VTA DA 
and GABA neurons [187, 188], to detect the presence of GIRK1, GIRK2, GIRK3, and 
GIRK4 mRNAs.  Constitutive Girk-/- mice could also be used to electrophysiologically 
characterize GIRK subunit contribution to GIRK-dependent signaling in RMTg GABA 
neurons. It is also possible that independent of GIRK channel subtype, GIRK-dependent 
signaling is not the primary mechanism through which opioids inhibit RMTg GABA 
neurons.  If this is the case, there are other postsynaptic mechanisms through which 
opioids could act that could be more relevant to the disinhibition of VTA DA neurons, 
and subsequent reward-related behavioral responses. 
The studies covered in Chapter 2 have challenged long-held assumptions about 
opioid signaling in the VTA.  We have shown that VTA DA neuron GIRK channel 
subunit composition can influence the behavioral sensitivity to opioids.  Further insight 
into the relevance of GIRK-dependent signaling in VTA DA neurons to morphine reward 
is required to determine whether it is possible to dissect the clinically beneficial outcomes 
(analgesia) from the undesirable side effects (addiction) of opioids.  
 
 
 
92	  
	  
The relevance of VTA DA neuron GIRK-dependent signaling to the cellular and 
reward-related behavioral effects of cocaine 
 Cocaine exposure has been shown to produce acute alterations and persistent 
synaptic adaptations to both excitatory and inhibitory signaling within the 
mesocorticolimbic DA system, with inhibitory changes linked to alterations in GPCR-
dependent signaling [91, 123, 150, 298, 299, 312-316].  Cocaine exposure results in 
increased extracellular DA levels, both in downstream targets and within the VTA.  
Extracellular DA in the VTA binds to inhibitory metabotropic receptors, D2Rs.  D2R 
activation represents a key autoinhibitory mechanism that tempers VTA DA 
neurotransmission, and it is mediated in large part by the activation of GIRK channels 
[299, 318, 319].  DA neurons express a unique GIRK channel, a heteromer containing 
GIRK2 and GIRK3 subunits [188].  To evaluate the behavioral impact of the loss of 
GIRK-dependent signaling in DA neurons, we created a novel conditional Girk2-/- mouse 
line, referred to as DATCre:Girk2flox/flox.   
Our previous work using the DATCre:Girk2flox/flox model showed that the selective 
loss of Girk2 in DA neurons attenuates baclofen- and opioid-induced currents in VTA 
DA neurons, while enhancing systemic opioid-induced locomotor stimulation [321]. 
Selective loss of Girk2 in DA neurons significantly blunted currents evoked by the D2R 
agonist quinpirole.  In addition to a reduction in inhibitory signaling, the DA neuron-
selective loss of Girk2 enhances both the acute and repeated locomotor-stimulatory 
response to cocaine; however, the importance of VTA DA GIRK-dependent signaling to 
cocaine reward (CPP) requires further evaluation. The impact Girk2 expression has on 
cocaine-induced locomotor activity suggests that the unique GIRK channel expressed in 
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VTA DA neurons may be a therapeutic target to regulate the sensitivity of the 
mesolimbic DA system to various drugs of abuse. 
Cocaine triggers enhanced excitatory neurotransmission within the 
mesocorticolimbic DA system [128, 338-342].  We have reported that the global loss of 
Girk2-/- results in enhanced excitatory neurotransmission in VTA DA neurons and the 
medium spiny neurons (MSNs) of the NAc [228].  Cocaine exposure also triggers a 
transient suppression of GIRK-dependent signaling and a reduction in GIRK membrane 
expression in the VTA and mPFC [187, 199].  The reported locomotor responses to acute 
and repeated cocaine in Chapter 3 are interesting given that the loss of GIRK-dependent 
signaling seems to pre-sensitize mice to the behavioral effects of cocaine.  Collectively, 
the results of these studies beg the question: what is the relationship between the cocaine-
induced suppression of GIRK channel activity and the cocaine-induced adaptation in 
excitatory signaling?  One possibility is that the cocaine-induced suppression of GIRK 
channel activity removes a threshold that allows for the enhancement of excitatory 
neurotransmission in the mesocorticolimbic DA system.  To test this hypothesis, we 
could measure excitatory neurotransmission following the selective loss of Girk2 in DA 
neurons.  These studies would look at miniature excitatory postsynaptic current 
(mEPSCs) amplitude and frequency in VTA DA and NAc MSNs of 
DATCre(+):Girk2flox/flox and control mice.   
One concern regarding the behavioral studies in Chapter 3 is the selectivity of the 
manipulations to VTA DA signaling in our DATCre(+):Girk2flox/flox mice.  The use of a 
transgenic Cre-driven ablation of a “floxed” gene, in this case Girk2, should remove the 
gene from all neurons expressing the DAT promoter.  DAT expression, while primarily 
94	  
	  
restricted to DA neurons, is not limited to the VTA.  Thorough characterization of this 
DATCre line shows that Cre expression is strong in other DAergic populations, including 
the substantia nigra [280, 343].  To support our assertion that the Cre-induced reduction 
in Girk2 expression is restricted to DA neurons, we have shown that changes to GIRK-
dependent signaling in DATCre(+):Girk2flox/flox mice are seen in VTA DA neurons but 
not VTA GABA neurons. This genetic approach to Girk2 ablation also means that Girk2 
is not present in DA neurons during development, allowing for compensatory adaptations 
to occur.  Since this is a more targeted loss of Girk2, we would not expect to see the same 
level of compensatory adaptations, notably enhanced mesocorticolimbic excitatory 
transmission, as we see with the global loss of Girk2; a possibility that still confounds 
clean interpretation of data.   
These initial findings in Chapter 3 regarding the role of GIRK-dependent 
signaling in the cellular and behavioral effects of cocaine were done with the 
DATCre(+/-):Girk2flox/flox mice line, meaning GIRK2-dependent signaling has been lost 
in all DA neurons.  To more specifically link GIRK-dependent signaling in VTA DA 
neurons to the cellular and behavioral effects of cocaine, we need to restrict our 
manipulations to DA neurons within the VTA.  One way to achieve this is through viral 
suppression of Girk2.  We have developed a Cre-dependent shRNA viral construct (LV-
CMV-eGFP-DIO-U6-shRNA) that targets Girk2, as well as a scrambled control.  Viral 
infusion targeting the VTA of DATCre(+) mice should restrict GIRK2 knockdown to DA 
neurons within the VTA [187, 321].  A Cre-dependent shRNA viral strategy offers many 
advantages to constitutive genetic manipulations, such as anatomic specificity and 
allowing Girk2 to be present throughout development until viral treatment in adulthood.  
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Based on our initial findings, it is expected that a viral knockdown of Girk2 would result 
in diminished baclofen- and quinpirole-induced currents.  If GIRK signaling in VTA DA 
neurons is critical to the reward-related behavioral effects of cocaine, we would also 
expect that mice experiencing a knockdown of Girk2 would exhibit enhanced motor-
stimulation and altered CPP compared to scrambled viral controls.   
There are many unanswered questions pertaining to the studies discussed in 
Chapter 3 that will require further examination.  Although we have seen that loss of 
GIRK2 in DA neurons alters the motor-stimulatory response to cocaine, with 
DATCre(+):Girk2flox/flox mice showing pre-sensitization to the initial exposure of cocaine, 
to answer our questions about the influence of GIRK-dependent signaling on cocaine 
reward, we need to test this mouse model using established reward-related behavioral 
paradigms, such as CPP and SA.  
Although we expect to see an enhanced magnitude of CPP from 
DATCre(+):Girk2flox/flox mice in our low-dose session dependent model, the CPP 
paradigm is not the best behavioral model of human addiction.  In the CPP behavioral 
paradigm, the drug is experimenter-administered and not contingent on the subject 
behavior.  Cocaine SA is a response-contingent paradigm where the subject must work to 
receive cocaine, and this is a more accurate model of human drug intake and willingness 
to work for the drug.  These studies would be done in collaboration with Dr. Michael 
Beckstead to look at what effect the loss of GIRK-dependent signaling in VTA DA 
neurons has on acquisition of cocaine SA [344].  We would also want to establish a dose-
response relationship for cocaine SA based on the differences we have seen in acute 
cocaine motor-stimulation.  My hypothesis is that the DATCre(+):Girk2flox/flox mice 
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would show enhanced SA and have more robust responses at lower doses of cocaine 
compared to DATCre(-):Girk2flox/flox controls, if in fact the loss of Girk2 in DA neurons 
enhances the subject’s sensitivity to cocaine.  Further insight into the relevance of GIRK-
dependent signaling in VTA DA neurons to cocaine reward could be useful to our 
understanding and the treatment of cocaine addiction. 
 
Future Directions 
VTA DA GIRK2/GIRK3 channel: a key regulator of the behavioral sensitivity to drugs 
of abuse 
The work discussed in this dissertation and additional studies from other labs, has 
implicated the unique GIRK channel subtype found in VTA DA neurons, the 
GIRK2/GIRK3 heteromer, in the sensitivity of the mesocorticolimbic DA system to 
circuit-level and behavioral effects of drugs of abuse [180, 188, 321].  Previous studies 
involving VTA DA neurons from Girk3-/- mice, which express GIRK2 homomeric 
channels in VTA DA neurons, are more sensitive to GPCR stimulation than wild-type 
counterparts [180].  The VTA DA GIRK channel has also been shown to play a role in 
the motor-stimulatory effect evoked by drugs of abuse.   Constitutive Girk2-/- mice have 
been shown to be more sensitive to the motor-stimulatory effect of cocaine and morphine 
[228], whereas, constitutive Girk3-/- mice appear to be less sensitive to the motor-
stimulatory effects of opioids and ethanol [321, 331, 332].  The work presented in 
Chapters 2 and 3 has shown that weakening GIRK channel activity (i.e. Girk2 ablation, 
no functional GIRK channels) in VTA DA neurons correlates with enhanced behavioral 
sensitivity to drugs of abuse, presumably reflecting a manifestation of enhanced DA 
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neurotransmission in downstream targets of the VTA in the mesocorticolimbic DA 
system.  Alternatively, enhancing GIRK channel activity (i.e. loss of Girk3, GIRK2 
homomeric channels) in VTA DA neurons correlates with decreased behavioral 
sensitivity to morphine, presumably reflecting reduced DA neurotransmission. These 
results would suggest that this unique GIRK channel subtype plays a vital role in 
controlling VTA DA activity, and may serve as a barrier to the rewarding effects of 
various drugs of abuse, such as morphine and cocaine.  Based on these findings 
therapeutic approaches, genetic or pharmacologic, targeting the activity of the 
GIRK2/GIRK3 channel might prove useful for treating some aspects of drug addiction. 
DATCre:Girk3flox/flox mouse line 
 To complement the studies we have done with the conditional Girk2-/- line 
looking at the relevance of GIRK-dependent signaling in VTA DA neurons to the 
rewarding effects of drugs of abuse, we have acquired a conditional Girk3-/- line from the 
Medical Research Council Harwell (strain: Kcnj9tm1a(EUCOMM)Hmgu).  These mice will be 
crossed with the DATCre line (strain: #006660, Jackson Labs) to generate a DA neuron 
specific loss of Girk3, DATCre:Girk3flox/flox mice.  To characterize this novel line, we 
would begin by crossing the DATCre:Girk3flox/flox line with our Pitx3-eGFP mouse line.  
The Pitx3-eGFP line allows for easier electrophysiological identification of DA neurons 
within the VTA, as they express eGFP under the control of a DA neuron-specific 
promoter, the Pitx3 gene.  Immunohistochemistry could be done on brain slices 
containing the VTA from DATCre(+):Girk3flox/flox and DATCre(-):Girk3flox/flox mice, 
staining for Girk3 (Cat# APC-038, Alomone labs) expression.   
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Functional validation of this line could also be done using whole-cell patch-clamp 
slice electrophysiology.  Previous work suggests that the DA neuron-selective loss of 
Girk3 should have no impact in our saturating concentration baclofen-current response 
assay, since constitutive ablation of Girk3 has no impact [180, 228].  To answer this 
question we would use a baclofen concentration-response protocol, and based on our 
hypothesis that the GIRK2/GIRK3 channel in VTA DA neurons can regulate the 
sensitivity to various drugs of abuse, we would expect to see that VTA DA neurons from 
DATCre(+):Girk3flox/flox mice were more sensitive to baclofen than VTA DA neurons 
from  DATCre(-):Girk3flox/flox controls.  In relation to the work done in Chapter 3, 
DATCre:Girk3flox/flox mice could then be used to test the impact of Girk3 ablation on 
D2R-depenendent signaling and DA neurotransmission in VTA DA neurons.  Assuming 
successful functional validation of DATCre:Girk3flox/flox line, we would assess the reward-
related behavioral effects of various drugs of abuse, such as morphine and cocaine, 
through similar efforts described in Chapters 2 and 3.  Based on our hypothesis that the 
strength of GIRK-dependent signaling in VTA DA neurons is a key regulatory of the 
behavioral sensitivity to drugs of abuse, I would expect that DATCre(+):Girk3flox/flox mice 
will exhibit reduced reward-related behavioral responses to morphine and cocaine, as 
compared to DATCre(-):Girk3flox/flox controls; this phenotype should be revealed by a 
downward shift in drug dose/reward-related behavior activity relationship.   
Selective GIRK2/GIRK3 pharmacology 
 The importance of GIRK channel function to many physiological processes 
makes them a logical candidate for various therapeutic indications.  However, due to the 
fact that GIRK channels are vital to proper cardiac function [345, 346], we must be able 
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to achieve regional and/or subunit-selective pharmacology to tap into the therapeutic 
potential of GIRK channels.  Until recently the compounds available for modulation of 
GIRK channel activity have lacked potency and selectivity, but a novel family of small 
molecule modulators of GIRK channels was discovered by Dr. C. David Weaver at 
Vanderbilt University, using high-throughput screen technology [279]. The compound 
ML297 has been shown to activate GIRK1-containing channels selectively, in a G 
protein-independent manner, through binding structures unique to the GIRK1 subunit 
[347].  ML297 was also shown to have therapeutic potential as an antiepileptic and 
anxiolytic compound, and it lacks significant reward liability as assessed by CPP [279, 
347].  The ability of ML297 to alter GIRK–dependent signaling in a subunit-dependent 
manner, with low abuse liability, represents a promising tool to further study the 
therapeutic potential of GIRK channel manipulations in other clinical disorders. 
Aside from analgesia, GIRK channel activity has also been linked to the 
development of addiction.  The work discussed in Chapters 2 and 3 has highlighted the 
importance of the unique VTA DA GIRK channel, the GIRK2/GIRK3 heteromer, to the 
sensitivity of various drugs of abuse. As shown in Chapters 2 and 3, removal of GIRK-
dependent signaling in VTA DA neurons, as shown in the DATCre(+):Girk2flox/flox mice, 
resulted in decrease inhibitory GPCR GIRK-dependent signaling and enhanced reward-
related behavioral responses. These findings suggest that the discovery of a 
GIRK2/GIRK3 channel selective compound, such as a GIRK2/GIRK3 selective agonist, 
could be useful as a therapeutic for the treatment and/or prevention of addiction to 
various drugs of abuse. 
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Concluding Thoughts 
Drug abuse is a critical global problem, with opioid and cocaine abuse being 
among the top offenders [3, 4]. With the high social and economic costs associated with 
illicit drug use, it is vital that we gain a better understanding of the cellular and molecular 
targets of drugs of abuse, and how modulation of these mechanisms can ultimately lead 
to the development of addiction. Much of the recent work in the field has focused on 
drug-induced adaptations to excitatory signaling within the mesocorticolimbic DA 
system; however, the adaptations and importance of inhibitory signaling requires further 
investigation. The goal of this dissertation was to enhance our understanding of the role 
of GIRK-dependent inhibitory signaling throughout the mesocorticolimbic DA system, 
and in particular, how it mediates the cellular and behavioral effects of drugs of abuse.   
The work discussed here has challenged the opioid signaling “dogma” and shown 
that GIRK-dependent signaling in midbrain GABA neurons is not required for 
disinhibition of VTA DA neurons and subsequent opioid-induced motor-stimulation.  
Rather, it appears the unique GIRK2/GIRK3 channel found in VTA DA neurons can 
regulate the behavioral sensitivity to morphine.  Interestingly, we found that this unique 
GIRK channel subtype can also modulate the behavioral sensitivity to cocaine, and 
possibly other drugs of abuse.  This work supports the feasibility of dissecting the 
clinically-desired analgesic effects from undesirable effects of opioids, by exploiting 
subunit differences in GIRK channel composition.   
Further, the discovery of ML297 and validation of its selectivity for GIRK1-
contaning channels gives us hope for GIRK subunit-selective compounds as useful 
therapeutics.  The work covered here would suggest that while important to the analgesic 
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effect of opioids in the spinal cord, GIRK1-containing channels do not seem to be vital to 
the reward-related behavioral effects of opioids.  These results, and the fact that ML297 
lacks significant reward liability as assessed by CPP, support further studies to examine 
the analgesic ability of ML297.  ML297 may be able to provide what current opioid 
therapies cannot, analgesia without the risk of tolerance and abuse.  The specificity and 
effectiveness of ML97 also gives hope for the discovery of a GIRK2/GIRK3 channel-
selective agonist that could be useful to reduce cravings or the propensity for relapse in 
addicts.  Collectively, the findings of these studies demonstrate that inhibitory signaling 
through GIRK channels in neurons of the VTA is critical to the molecular and behavioral 
effects of drugs of abuse, and suggest that novel compounds that modulate GIRK channel 
function in a subunit-dependent manner could help us prevent and/or treat addiction.   
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